



CONSOLIDATED FINANCIAL REPORT,
SUPPLEMENTARY INFORMATION, UNIFORM
GUIDANCE REPORTS AND SCHEDULE

Mayo Clinic
Years Ended December 31, 2024 and 2023



The better the question.
The better the answer.
The better the world works.



Shape the future
with confidence

Mayo Clinic

Consolidated Financial Report, Supplementary Information, Uniform Guidance Reports and Schedule

Years Ended December 31, 2024 and 2023

Contents

Independent auditor's report	1
Consolidated financial statements	
Consolidated statements of financial position	4
Consolidated statements of activities.....	5
Consolidated statements of cash flows	6
Notes to consolidated financial statements	7
Supplementary Information	
Schedule of Expenditures of Federal Awards.....	42
Schedule of Expenditures of Florida State Financial Assistance.....	91
Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance	92
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	94
Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, <i>Rules of the Auditor General of the State of Florida</i>	96
Schedule of Findings and Questioned Costs.....	102



Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

**Shape the future
with confidence**

Report of Independent Auditors

Board of Trustees
Mayo Clinic

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2024 and 2023, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Clinic at December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Clinic, and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.



**Shape the future
with confidence**

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



**Shape the future
with confidence**

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to March 3, 2025. The Schedules of Expenditures of Federal Awards and Florida State Financial Assistance as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, respectively, are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated March 3, 2025 on our consideration of the Clinic's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Clinic's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Clinic's internal control over financial reporting and compliance.

Ernst + Young LLP

March 3, 2025, except for the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance, for which the date is July 31, 2025



Consolidated Statements of Financial Position
December 31, 2024 and 2023 (In Millions)

	2024	2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 48	\$ 80
Accounts receivable for medical services	2,123	1,976
Other receivables	707	787
Other current assets	456	391
Total current assets	<u>3,334</u>	<u>3,234</u>
Investments	20,958	18,834
Other long-term assets	4,614	3,428
Property, plant, and equipment, net	7,099	6,431
Total assets	<u>\$ 36,005</u>	<u>\$ 31,927</u>
Liabilities and net assets		
Current liabilities:		
Accounts payable	\$ 778	\$ 847
Accrued payroll	1,004	873
Accrued employee benefits	178	181
Deferred revenue	88	65
Long-term variable-rate debt	620	620
Other current liabilities	629	491
Total current liabilities	<u>3,297</u>	<u>3,077</u>
Long-term debt, net of current portion	3,989	4,098
Accrued pension and postretirement benefits, net of current portion	827	813
Other long-term liabilities	2,435	2,303
Total liabilities	<u>10,548</u>	<u>10,291</u>
Net assets:		
Without donor restrictions	19,644	16,240
With donor restrictions	5,813	5,396
Total net assets	<u>25,457</u>	<u>21,636</u>
Total liabilities and net assets	<u>\$ 36,005</u>	<u>\$ 31,927</u>

See notes to consolidated financial statements.



Consolidated Statements of Activities
Years Ended December 31, 2024 and 2023 (In Millions)

	2024			2023		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains and other support:						
Medical service revenue	\$ 16,554	\$ —	\$ 16,554	\$ 15,077	\$ —	\$ 15,077
Grants and contracts	772	—	772	703	—	703
Investment return allocated to current activities	432	46	478	479	57	536
Contributions available for current activities	252	288	540	127	301	428
Other	1,451	—	1,451	1,200	—	1,200
Net assets released from restrictions	444	(444)	—	442	(442)	—
Total revenue, gains and other support	19,905	(110)	19,795	18,028	(84)	17,944
Expenses:						
Salaries and benefits	10,482	—	10,482	9,667	—	9,667
Supplies and services	6,731	—	6,731	5,950	—	5,950
Depreciation and amortization	685	—	685	663	—	663
Facilities	415	—	415	388	—	388
Finance and investment	189	—	189	192	—	192
Total expenses	18,502	—	18,502	16,860	—	16,860
Income (loss) from current activities	1,403	(110)	1,293	1,168	(84)	1,084
Noncurrent and other items:						
Contributions not available for current activities, net	(16)	176	160	(17)	190	173
Unallocated investment (loss) return, net	961	351	1,312	788	227	1,015
Income tax expense	(41)	—	(41)	(41)	—	(41)
Benefit Credit	324	—	324	344	—	344
Other	(142)	—	(142)	(162)	—	(162)
Total noncurrent and other items	1,086	527	1,613	912	417	1,329
Increase (decrease) in net assets before other changes in net assets	2,489	417	2,906	2,080	333	2,413
Pension and other postretirement benefit adjustments	930	—	930	(648)	—	(648)
Purchase of non-controlling interest	(15)	—	(15)	—	—	—
Increase (decrease) in net assets	3,404	417	3,821	1,432	333	1,765
Net assets at beginning of year	16,240	5,396	21,636	14,808	5,063	19,871
Net assets at end of year	\$ 19,644	\$ 5,813	\$ 25,457	\$ 16,240	\$ 5,396	\$ 21,636

See notes to consolidated financial statements.



Consolidated Statements of Cash Flows
Years Ended December 31, 2024 and 2023 (In Millions)

	2024	2023
Cash flows from operating activities:		
Cash from medical services	\$ 15,418	\$ 14,016
Cash from external lab services	989	927
Cash from grants and contracts	785	671
Cash from benefactors	445	373
Cash from other activities	1,440	1,051
Cash for salaries and benefits	(10,236)	(9,576)
Cash for supplies, services, and facilities	(7,225)	(6,212)
Interest and dividends received	367	303
Interest paid	(177)	(173)
Income taxes paid	(26)	(62)
Net cash provided by operating activities	<u>1,780</u>	<u>1,318</u>
Cash flows from investing activities:		
Purchase of property, plant, and equipment	(1,341)	(1,164)
Purchases of investments	(21,205)	(13,766)
Sales and maturities from investments	20,503	13,467
Investment in unconsolidated entities	75	(9)
Net cash used in investing activities	<u>(1,968)</u>	<u>(1,472)</u>
Cash flows from financing activities:		
Restricted gifts, bequests, and other	198	213
Purchase of non-controlling interest	(15)	—
Payment of long-term debt	(18)	(36)
Payment on leases	(9)	(7)
Net cash provided by financing activities	<u>156</u>	<u>170</u>
Net increase (decrease) in cash and cash equivalents	<u>(32)</u>	<u>16</u>
Cash and cash equivalents at beginning of year	80	64
Cash and cash equivalents at end of year	<u>\$ 48</u>	<u>\$ 80</u>

See notes to consolidated financial statements.

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies

Organization: Mayo Clinic and its Arizona, Florida, Iowa, Minnesota, Wisconsin and international affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

Basis of presentation: Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entities*.

Use of estimates: The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Standards:

Effective January 1, 2023, the Clinic adopted FASB Accounting Standard Update (ASU) No. 2016-13, *Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*. This ASU provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other documents to extend credit held by a reporting entity. The adoption of this ASU did not materially impact the consolidated financial statements.

Effective January 1, 2024, the Clinic adopted FASB Accounting Standard Update (ASU) No. 2023-01, *Leases - Common Control Arrangements*. This ASU requires entities determine whether a related party arrangement between entities under common control is a lease and requires that leasehold improvements have an amortization period consistent with the shorter of the remaining lease term and the useful life of the improvements for a lease between entities under common control. The adoption of this ASU did not materially impact the consolidated financial statements.

Cash and cash equivalents: Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

Accounts receivable for medical services: Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

Inventories: Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

Investments: Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 6). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest, and dividends) is included in the consolidated statements of activities.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate and natural resources funds) represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements, as a practical expedient. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a formula, which involves allocating five percent of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its investments over the long term. The unallocated investment return, included in noncurrent and other items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

Property, plant, and equipment: Property, plant, and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from three to fifty years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

Leases: The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant, and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of twelve months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Deferred revenue: Deferred revenue consists of payments received in advance for grant, subscription, and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

Deferred compensation: The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. The compensation deferred under this plan is credited with earnings and losses as determined by the rate of return on investments selected by the plan participants. Each participant is fully vested in all deferred compensation and those earnings credited to their individual accounts. The amounts deferred under this plan is an unsecured obligation of the Clinic. The balances are reflected in investments and other long-term liabilities in the consolidated statements of financial position. The related investment return is reported in unallocated investment return, net, with a corresponding gain/loss representing benefit expense/income reported in the other - noncurrent section of the consolidated statements of activities.

Asset retirement obligations: The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

Net assets: Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net Assets With Donor Restrictions - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Medical service revenue: Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

Grants and contracts: Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement. Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

Charity and uncompensated care: The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was \$130 and \$58 in 2024 and 2023, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled \$622 and \$624 in 2024 and 2023, respectively.

Contributions: The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities. Development expenses of \$67 (\$51 allocated to current and \$16 allocated to noncurrent) and \$59 (\$42 allocated to current and \$17 allocated to noncurrent) were incurred in 2024 and 2023, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification.

Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

Income from current activities: The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

Noncontrolling interest in subsidiaries: The Clinic attributed income of \$5 and \$6 for the years ended December 31, 2024 and 2023, respectively, to noncontrolling interests based on the ownership percentage of the noncontrolling interests in certain of the Clinic's consolidated subsidiaries. These amounts are recognized in net assets without donor restrictions on the consolidated statements of financial position. The balance in net assets without donor restrictions was \$58 and \$68 for the years ended December 31, 2024 and 2023, respectively.

Subsequent events: The Clinic evaluated events and transactions occurring subsequent to December 31, 2024 through March 3, 2025, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure.

Notes to Consolidated Financial Statements (In Millions)

Note 2. Liquidity and Availability

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are composed of the following at December 31:

	2024	2023
Cash and cash equivalents	\$ 48	\$ 80
Accounts receivable	2,123	1,976
Promises to give	245	325
Grants receivable	160	173
Other receivables	302	289
Investments	12,903	12,750
Total financial assets available within one year	<u>\$ 15,781</u>	<u>\$ 15,593</u>

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has \$300 of available lines of credit for working capital (see Note 9 - Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 13 - Endowment, under the Clinic spending policy, \$311 from the endowments was available as of January 1, 2025 and \$303 from the endowments was available at January 1, 2024.

Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2024 and 2023, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years was \$10 and \$12, respectively. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2024 and 2023, was not significant.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available) or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price for the years ended December 31, 2024 and 2023 were not significant. Receivables from third-party payors for final settlements was \$57 and \$64 at December 31, 2024 and 2023, respectively.

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2024 and 2023, are as follows:

	Year Ended December 31, 2024			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,970	\$ 1,407	\$ 1,809	\$ 9,186
Clinic	4,077	1,057	1,104	6,238
Senior Care and Nursing Home	16	—	—	16
Other	103	1	—	104
Total patient care service revenue	10,166	2,465	2,913	15,544
External lab	1,010	—	—	1,010
Total medical service revenue	\$ 11,176	\$ 2,465	\$ 2,913	\$ 16,554
Timing of revenue and recognition:				
At time services are rendered	\$ 5,190	\$ 1,058	\$ 1,104	\$ 7,352
Services transferred over time	5,986	1,407	1,809	9,202
Total	\$ 11,176	\$ 2,465	\$ 2,913	\$ 16,554
	Year Ended December 31, 2023			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,583	\$ 1,271	\$ 1,566	\$ 8,420
Clinic	3,645	957	1,020	5,622
Senior Care and Nursing Home	15	—	—	15
Other	94	2	—	96
Total patient care service revenue	9,337	2,230	2,586	14,153
External lab	924	—	—	924
Total medical service revenue	\$ 10,261	\$ 2,230	\$ 2,586	\$ 15,077
Timing of revenue and recognition:				
At time services are rendered	\$ 4,663	\$ 959	\$ 1,020	\$ 6,642
Services transferred over time	5,598	1,271	1,566	8,435
Total	\$ 10,261	\$ 2,230	\$ 2,586	\$ 15,077

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. The Clinic's practice is to record certain radiology, pathology, and other hospital related services in the Midwest region as clinic revenue in the amount of \$1,268 and \$1,130 for the years ended December 31, 2024 and 2023, respectively. Examples of revenue at the time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2024	2023
Medicare	\$ 4,439	\$ 4,029
Medicaid	607	561
Contract	9,695	8,853
Other, including self-pay	1,813	1,634
Total	<u>\$ 16,554</u>	<u>\$ 15,077</u>

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

A financial instruments categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2024 and 2023.

The following tables present the financial instruments carried at fair value as of December 31, 2024 and 2023, on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

	December 31, 2024				Total Fair Value
	Level 1	Level 2	Level 3	NAV	
Assets:					
Securities lending collateral	\$ 30	\$ —	\$ —	\$ —	\$ 30
Investments:					
Cash and cash equivalents	1,464	161	—	—	1,625
Fixed-income securities:	—	2,244	—	—	2,244
U.S. government	—	933	—	—	933
U.S. government agencies	—	1,016	—	—	1,016
U.S. corporate	—	26	—	—	26
Foreign	—	—	—	—	—
Common and preferred stocks:					
U.S.	1,284	—	—	—	1,284
Foreign	711	—	—	—	711
Funds:					
Fixed income	452	—	—	—	452
Equities	1,346	751	—	—	2,097
Less securities under lending agreement	(76)	—	—	—	(76)
Investments at NAV	—	—	—	10,570	10,570
Total investments	\$ 5,181	\$ 5,131	\$ —	\$ 10,570	\$ 20,882
Investments under securities lending agreement	\$ 76	\$ —	\$ —	\$ —	\$ 76
Other long-term assets:					
Trust receivables	\$ 70	\$ 29	\$ 247	\$ —	\$ 346
Technology-based ventures	\$ —	\$ —	\$ 295	\$ —	\$ 295
Total other long-term assets	\$ 70	\$ 29	\$ 542	\$ —	\$ 641
Total assets at fair value	\$ 5,357	\$ 5,160	\$ 542	\$ 10,570	\$ 21,629
Liabilities:					
Securities lending payable	\$ 30	\$ —	\$ —	\$ —	\$ 30
Total liabilities at fair value	\$ 30	\$ —	\$ —	\$ —	\$ 30

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2023				Total Fair Value
	Level 1	Level 2	Level 3	NAV	
Assets:					
Securities lending collateral	\$ 10	\$ —	\$ —	\$ —	\$ 10
Investments:					
Cash and cash equivalents	1,137	66	—	—	1,203
Fixed-income securities:	—	1,969	—	—	1,969
U.S. government	—	840	—	—	840
U.S. government agencies	—	918	—	—	918
U.S. corporate	—	51	—	—	51
Foreign	—	—	—	—	—
Common and preferred stocks:					
U.S.	1,391	—	—	—	1,391
Foreign	858	—	20	—	878
Funds:					
Fixed income	398	—	—	—	398
Equities	1,107	716	—	—	1,823
Less securities under lending agreement	(86)	—	—	—	(86)
Investments at NAV	—	—	—	9,363	9,363
Total investments	\$ 4,805	\$ 4,560	\$ 20	\$ 9,363	\$ 18,748
Investments under securities lending agreement	\$ 86	\$ —	\$ —	\$ —	\$ 86
Other long-term assets:					
Trust receivables	\$ 69	\$ 29	\$ 120	\$ —	\$ 218
Technology-based ventures	\$ —	\$ —	\$ 268	\$ —	\$ 268
Total other long-term assets	\$ 69	\$ 29	\$ 388	\$ —	\$ 486
Total assets at fair value	\$ 4,970	\$ 4,589	\$ 408	\$ 9,363	\$ 19,330
Liabilities:					
Securities lending payable	\$ 10	\$ —	\$ —	\$ —	\$ 10
Total liabilities at fair value	\$ 10	\$ —	\$ —	\$ —	\$ 10

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, composed primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors that would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2024, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 4,796	\$ 414	Monthly to annually	30–90 days
Private partnerships (b)	5,774	1,897		
Total alternative investments	<u>\$ 10,570</u>	<u>\$ 2,311</u>		

At December 31, 2023, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 4,254	\$ 388	Monthly to annually	30–90 days
Private partnerships (b)	5,109	2,043		
Total alternative investments	<u>\$ 9,363</u>	<u>\$ 2,431</u>		

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic’s ownership interest in partners’ capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

From time to time, the Clinic invests directly in certain derivative contracts that do not qualify for hedge accounting and are recorded at fair value in investments. Changes in fair value are reported as a component of net unrealized gains or losses in the investment returns. These contracts are used in the Clinic’s investment management program to minimize certain investment risks. During the years ended December 31, 2024 and 2023, the realized and unrealized loss from derivative contracts was not significant.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2024 and 2023 was \$1,020 (6.6 percent) and \$881 (6.3 percent), respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were \$1,320 and \$1,142, respectively, at December 31, 2024 and 2023, which includes segregated investments for deferred compensation plans of \$1,317 and \$1,129 at December 31, 2024 and 2023, respectively.

At December 31, 2024 and 2023, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of \$126 and \$116, respectively.

The Clinic had internally designated investment balances of \$3,324 and \$3,181 at December 31, 2024 and 2023, respectively, for research, education, and capital replacement and expansion.

Note 5. Investments in Unconsolidated Entities

The Clinic holds certain investments in unconsolidated entities accounted for in accordance with FASB Subtopic 323, *Investments - Equity Method and Joint Ventures*. The investments are presented as other long-term assets in the consolidated statements of financial position. The Clinic's interest in the investment income is reflected in the accompanying consolidated statements of operations.

The following table presents investments in unconsolidated entities:

	Ownership Percentage as of December 31, 2024	Carrying Value as of December 31, 2024	Carrying Value as of December 31, 2023
Sheikh Shakhbout Medical City	—%	\$ —	\$ 157
Other investees	Various	\$ 3	\$ 7

The Clinic entered into a joint venture agreement with Abu Dhabi Health Services Company PJSC (SEHA) to operate Sheikh Shakhbout Medical City (SSMC), a 741-bed hospital in the United Arab Emirates in November 2019. In addition to the joint venture agreement, the Clinic entered into a hospital expertise agreement, brand license agreement, and research contribution agreement with SSMC. The joint venture had an initial commitment period of twenty years which would have been extended by ten years if neither party terminated at the conclusion of the initial commitment period. The Clinic had a \$150 conditional pledge from Sheikh Shakhbout Medical City at December 31, 2023. SEHA acquired the Clinic's interest in SSMC with the transaction successfully closing in the first quarter of 2024. As part of this transaction, the parties also terminated the joint venture and related agreements.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 5. Investments in Unconsolidated Entities (Continued)

The summarized financial position and results of operations for SSMC accounted for under the equity method as of and for the years ended consisted of the following:

	2024	2023
As of December 31		
Total assets	\$ —	\$ 842
Total liabilities	\$ —	\$ 236
Partners equity/net assets	\$ —	\$ 842
Year Ended December 31		
Total revenue	\$ —	\$ 586
Gain (loss) from current activities	\$ —	\$ 4

Note 6. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit.

Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

At December 31, 2024 and 2023, the aggregate market value of securities on loan under securities lending agreements totaled \$76 and \$86, respectively, and the total value of the collateral supporting the securities was \$79 and \$90, respectively, which represents 104% of the value of the securities on loan at December 31, 2024 and 2023. The cash portion of the collateral supporting the securities as of December 31, 2024 and 2023 was \$30 and \$10, respectively. The cash portion is presented in other current assets and other current liabilities in the consolidated statements of financial position. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

Note 7. Property, Plant, and Equipment, Net

Property, plant, and equipment, net, at December 31 consisted of the following:

	2024	2023
Land	\$ 620	\$ 589
Buildings and improvements	8,629	7,663
Furniture and equipment	4,926	4,693
	14,175	12,945
Accumulated depreciation and amortization	(8,082)	(7,618)
	6,093	5,327
Construction in progress	1,006	1,104
Total property, plant, and equipment	\$ 7,099	\$ 6,431

Notes to Consolidated Financial Statements (In Millions)

Note 7. Property, Plant, and Equipment, Net (Continued)

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was \$763 and \$771 at December 31, 2024 and 2023, respectively. The total accumulated amortization was \$608 and \$582 at December 31, 2024 and 2023, respectively. Amortization expense for capitalized software was \$70 and \$67 in 2024 and 2023, respectively.

Note 8. Income Taxes

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income. The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2021 through 2023 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Internal Revenue Service (IRS) performed an examination of the tax and information returns of the Clinic and two subsidiaries and ultimately assessed \$12 in taxes for years 2003-2012. The results of this audit were litigated in the U.S. District Court. On August 6, 2019, the Court issued a summary judgment in favor of the Clinic. The IRS appealed this decision and on May 13, 2021, the Eighth Circuit Court of Appeals reversed the summary judgment and remanded the case to the U.S. District Court for trial. The case was tried in 2022 and the U.S. District Court issued a judgment in favor of the Clinic on December 9, 2022. The IRS disagreed with this ruling and filed an appeal with the Eighth Circuit Court of Appeals on September 1, 2023. Oral Arguments were made before the Eighth Circuit Court of Appeals on October 23, 2024, but the Court has not yet issued its ruling. No adjustment has been made to unrecognized tax benefits as the issue has not been definitively resolved at this time.

The Clinic has increased the reserve for uncertain tax positions by \$5, including interest and penalties, during the year ended December 31, 2024. As of December 31, 2024 and 2023, the reserve totaled \$14 and \$9, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2024	2023
Current—federal	\$ 41	\$ 28
Current—state	6	7
	47	35
Deferred—U.S. domestic	(6)	6
Total	\$ 41	\$ 41

Cash payments for income taxes were \$26 and \$62 for the years ended December 31, 2024 and 2023, respectively.

Notes to Consolidated Financial Statements (In Millions)

Note 8. Income Taxes (Continued)

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2024	2023
Deferred compensation	\$ 10	\$ 9
Postretirement benefits	—	1
Net operating loss	21	2
Other	5	4
Total deferred tax asset	36	16
Deferred tax liability	(1)	(2)
Valuation allowance	(27)	(10)
Net deferred tax asset	\$ 8	\$ 4

The Clinic had federal net operating losses of \$22 and \$11 at December 31, 2024 and 2023, respectively.

The Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017 repealed Net Operating Loss (NOL) carrybacks while permitting indefinite carryforwards. The Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020 temporarily suspended TCJA repeal of NOL carrybacks allowing for NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to the five taxable years preceding the taxable year of such loss. During 2024, the Clinic was able to carryback the remaining \$6 of the NOLs arising in tax years beginning after December 31, 2017. Of the NOLs arising after January 1, 2018, \$22 will be carried forward.

Note 9. Financing

Long-term debt at December 31 consisted of the following:

		2024	2023
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 3.42% in 2024 and 3.47% in 2023), principal due in varying amounts from 2028 through 2052	Variable	\$ 545	\$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2025 through 2032	Fixed	110	127
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	130
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed rate of interest of 4.00%, principal due in varying amounts from 2044 through 2048	Fixed	200	200

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 9. Financing (Continued)

	2024	2023	
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with a coupon 5.00%, an effective rate of 2.97% in 2024 and 2023 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of \$37 in 2024 and \$42 in 2023)	Fixed	220	220
City of Rochester, Minnesota Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.25% to 5.00%, an effective rate of 3.74% in 2024 and 2023 after amortization of premium principal due in varying amounts from 2039 through 2057 (unamortized net premium of \$15 in 2024 and \$16 in 2023)	Fixed	289	289
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 2.97% in 2024 and 3.51% in 2023), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 3.51% in 2024 and 3.55% in 2023), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.20% to 4.13%, principal due in varying amounts from 2039 through 2061	Fixed	1,450	1,450
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.80% to 4.71%, principal due in varying amounts from 2025 through 2062	Fixed	1,115	1,115
The Industrial Development Authority of the City of Phoenix, Arizona Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.75% to 4.00%, an effective rate of 3.80% in 2024 and 2023 after amortization of premium, principal due in varying amounts from 2053 to 2057 (unamortized net premium of \$3 in 2024 and 2023)	Fixed	298	298
Other notes payable		10	11
Unamortized discounts and premiums, net		55	61
Debt issuance cost		(13)	(15)
		4,714	4,736
Long-term variable-rate debt classified as current		(620)	(620)
Current maturities included in other current liabilities		(105)	(18)
Long-term debt, net of current portion		\$ 3,989	\$ 4,098

Notes to Consolidated Financial Statements (In Millions)

Note 9. Financing (Continued)

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2024, the \$850 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of \$230 of which \$140 will expire in January 2026 and \$90 will expire in January 2030. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2025. The Clinic has provided self-liquidity for the remaining \$620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The \$220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2025 to 2058 at the option of the Clinic, at a redemption price of 100 percent of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, \$620 may be due in 2025 and \$230 may be due in years from 2026 to 2030.

Years ending December 31:		
2025	\$	105
2026		5
2027		105
2028		45
2029		67

Interest payments on long-term debt, net of amounts capitalized for 2024 and 2023, totaled \$151 and \$154, respectively. The amount of interest capitalized, net of related interest income, was \$17 and \$12 during 2024 and 2023. Interest expense totaled \$155 and \$157 for 2024 and 2023, respectively.

At December 31, 2024 and 2023, the Clinic had unsecured lines of credit available with banks that totaled \$530, with varying renewable terms and interest up to 2.50 percent over various published rates. There were no amounts drawn during the years ended December 31, 2024 and 2023.

Note 10. Leases

At December 31, 2024 and 2023, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)**

Note 10. Leases (Continued)

Total lease expense for the years ended December 31 consisted of the following:

	2024	2023
Operating lease expense	\$ 31	\$ 30
Finance lease expense:		
Amortization of right-of-use assets	\$ 10	\$ 6
Interest on lease liabilities	1	1
Total finance lease expense	\$ 11	\$ 7
Short-term lease expense	\$ 29	\$ 48

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 62	\$ 57
Operating cash flows for finance leases	1	1
Financing cash flows for finance leases	9	7
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 34	\$ 25
Finance leases	12	24

Consolidated supplemental statement of financial position information related to leases as of the years ended December 31 consisted of the following:

	2024	2023
Operating leases:		
Right-of-use assets	\$ 136	\$ 122
Other current liabilities	\$ 26	\$ 22
Other long-term liabilities	137	127
Total operating lease liabilities	\$ 163	\$ 149

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 10. Leases (Continued)

	2024	2023
Finance leases:		
Property, plant, and equipment, gross	\$ 60	\$ 76
Accumulated depreciation	23	38
Property, plant, and equipment, net	<u>\$ 37</u>	<u>\$ 38</u>
Other current liabilities	\$ 8	\$ 9
Other long-term liabilities	29	27
Total finance lease liabilities	<u>\$ 37</u>	<u>\$ 36</u>
Weighted average remaining lease years:		
Operating leases	8.25	8.94
Finance leases	4.94	5.39
Weighted average discount rate:		
Other long-term liabilities	3.50%	3.44%
Total finance lease liabilities	<u>3.53%</u>	<u>3.38%</u>

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2025	\$ 30	\$ 10
2026	28	8
2027	25	8
2028	23	6
2029	16	5
Thereafter	70	3
Minimum lease payments	<u>192</u>	<u>40</u>
Less amount representing interest	29	3
Net minimum lease payments	<u>\$ 163</u>	<u>\$ 37</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 11. Board-Designated Funds

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2024	2023
Research	\$ 1,659	\$ 1,581
Education	344	327
Buildings and equipment	3	3
Charity care	14	13
Clinical	168	164
Other	1,136	1,093
Total designation for specified purpose	<u>\$ 3,324</u>	<u>\$ 3,181</u>

At December 31, board designated funds were classified as follows:

	2024	2023
Quasi-endowments	\$ 3,113	\$ 2,967
Professional liability reserve	178	185
Other	33	29
Total	<u>\$ 3,324</u>	<u>\$ 3,181</u>

Note 12. Net Assets with Donor Restrictions

The Clinic receives contributions in support of research, education, and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2024	2023
Subject to expenditure for specified purposes:		
Research	\$ 749	\$ 686
Education	64	59
Buildings and equipment	199	180
Charity care	34	32
Clinical	86	89
Other	44	38
Total expenditure for specified purposes	<u>1,176</u>	<u>1,084</u>
Subject to passage of time:		
Pledges and trusts	<u>730</u>	<u>682</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 12. Net Assets with Donor Restrictions (Continued)

	2024	2023
Endowments:		
Perpetual in nature:		
Research	\$ 1,332	\$ 1,263
Education	374	355
Charity care	15	14
Clinical	223	224
Other	63	50
Pledges and trusts	272	269
Total perpetual in nature	2,279	2,175
Subject to endowment spending policy:		
Research	931	824
Education	408	370
Charity care	56	52
Clinical	185	166
Other	48	43
Total subject to endowment spending policy	1,628	1,455
Total endowments	3,907	3,630
Total net assets with donor restrictions	\$ 5,813	\$ 5,396

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2024	2023
Research	\$ 292	\$ 200
Education	38	30
Buildings and equipment	74	181
Other	40	31
Total net assets released from donor restrictions	\$ 444	\$ 442

Note 13. Endowment

The Clinic's endowment consists of approximately 2,500 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to re-designate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the

Notes to Consolidated Financial Statements (In Millions)

Note 13. Endowment (Continued)

permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least five percent over the long term. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year five percent of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2024, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,907	\$ 3,907
Quasi-endowments	3,113	—	3,113
Total funds	<u>\$ 3,113</u>	<u>\$ 3,907</u>	<u>\$ 7,020</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 13. Endowment (Continued)

Changes in endowment net assets for the year ended December 31, 2024, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,967	\$ 3,630	\$ 6,597
Investment return:			
Investment income	40	46	86
Net appreciation (realized and unrealized)	249	286	535
Total investment return	289	332	621
Contributions	—	103	103
Appropriation of endowment assets for expenditure	(170)	(158)	(328)
Other changes:			
Transfers to create quasi-endowments	27	—	27
Endowment net assets, end of year	\$ 3,113	\$ 3,907	\$ 7,020

At December 31, 2023, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,630	\$ 3,630
Quasi-endowments	2,967	—	2,967
Total funds	\$ 2,967	\$ 3,630	\$ 6,597

Changes in endowment net assets for the year ended December 31, 2023, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,830	\$ 3,401	\$ 6,231
Investment return:			
Investment income	39	44	83
Net appreciation (realized and unrealized)	204	225	429
Total investment return	243	269	512
Contributions	—	102	102
Appropriation of endowment assets for expenditure	(167)	(142)	(309)
Other changes:			
Transfers to create quasi-endowments	61	—	61
Endowment net assets, end of year	\$ 2,967	\$ 3,630	\$ 6,597

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 14. Promises to Give

At December 31, outstanding pledges from various corporations, foundations, and individuals, included in other receivables and other long-term assets, were as follows:

	2024	2023
Pledges due:		
In less than one year	\$ 245	\$ 325
In one to five years	330	311
In more than five years	39	65
	614	701
Allowance for uncollectible pledges and discounts	(28)	(30)
Total	\$ 586	\$ 671

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1 percent to 6 percent, that is commensurate with the pledges due dates and established in the year the pledge is received.

The Clinic has received interests in various trusts, primarily split-interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 5.43 percent and 5.77 percent at December 31, 2024 and 2023, respectively. During the years ended December 31, 2024 and 2023, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was \$346 and \$218 at December 31, 2024 and 2023, respectively.

Note 15. Functional Expenses

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2024 and 2023 supported the following programs and functions:

	2024							
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses
Salaries and benefits	\$ 8,685	\$ 213	\$ 807	\$ 425	\$ 257	\$ 33	\$ 62	\$ 10,482
Supplies and services	4,723	1,314	347	102	105	16	124	6,731
Depreciation and amortization	561	8	74	14	23	1	4	685
Facilities	311	6	24	15	56	1	2	415
Finance and investment	186	8	19	2	4	—	(30)	189
Total	\$ 14,466	\$ 1,549	\$ 1,271	\$ 558	\$ 445	\$ 51	\$ 162	\$ 18,502

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 15. Functional Expenses (Continued)

	2023							Total expenses
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	
Salaries and benefits	\$ 7,982	\$ 190	\$ 728	\$ 392	\$ 290	\$ 28	\$ 57	\$ 9,667
Supplies and services	4,231	1,132	299	94	46	12	136	5,950
Depreciation and amortization	552	8	69	13	16	1	4	663
Facilities	311	6	20	14	34	1	2	388
Finance and investment	168	10	20	2	2	—	(10)	192
Total	\$ 13,244	\$ 1,346	\$ 1,136	\$ 515	\$ 388	\$ 42	\$ 189	\$ 16,860

Note 16. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2024 and 2023, are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of \$317 and \$620 and unrecognized prior service benefit of \$109 and \$102. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed ten percent of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2024 and 2023 included the following:

	2024	2023
Current-year actuarial gain (loss)	\$ 936	\$ (482)
Amortization of actuarial loss	1	(1)
Current-year prior service cost	—	(116)
Amortization of prior service credit	(7)	(49)
Pension and other postretirement benefit adjustments	\$ 930	\$ (648)

Pension plans:

Obligations and funded status: The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

	2024	2023
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$ 8,889	\$ 7,809
Service cost	426	383
Interest cost	468	436
Actuarial (gain) loss	(796)	572
Benefits paid	(412)	(424)
Plan amendments	—	113
Estimated benefit obligation at end of year	\$ 8,575	\$ 8,889

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

	2024	2023
Change in plan assets:		
Fair value of plan assets, beginning of year	\$ 10,702	\$ 9,965
Actual return on plan assets	996	878
Employer contributions	281	283
Benefits paid	(412)	(424)
Fair value of plan assets at end of year	<u>\$ 11,567</u>	<u>\$ 10,702</u>

	2024	2023
Funded status of the plans	<u>\$ 2,992</u>	<u>\$ 1,813</u>
Accumulated benefit obligation	<u>\$ (7,803)</u>	<u>\$ (8,094)</u>

Amounts recognized in the consolidated statements of financial position consist of the following at December 31:

	2024	2023
Noncurrent assets	\$ 2,993	\$ 1,814
Noncurrent liabilities	(1)	(1)
Net amount recognized	<u>\$ 2,992</u>	<u>\$ 1,813</u>

Components of net periodic benefit cost are as follows for the years ended December 31:

	2024	2023
Service cost	\$ 426	\$ 383
Interest cost	468	436
Expected return on plan assets	(831)	(778)
Amortization of unrecognized:		
Prior service benefit	(8)	(50)
Net periodic benefit cost	<u>\$ 55</u>	<u>\$ (9)</u>

Plan assets: The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds \$11,434 of the \$11,567 in combined plan assets at December 31, 2024, and \$10,574 of the \$10,702 in combined plan assets at December 31, 2023. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5 percent. The portfolio's target fixed-income exposure is 17.5 percent. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 35 percent (with a target allocation of 25 percent), and exposure to absolute return strategies is limited to a maximum of 30 percent (with a target of 25 percent). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

The fair values of the Plan's assets at December 31, 2024, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 596	\$ 9	\$ —	\$ —	\$ 605
Fixed income securities:					
U.S. government	—	199	—	—	199
U.S. government agencies	—	207	—	—	207
U.S. corporate	—	350	—	—	350
Foreign	—	16	—	—	16
Common and preferred stocks:					
U.S.	1,028	—	—	—	1,028
Foreign	529	—	—	—	529
Funds:					
Fixed income	123	—	—	—	123
Equities	60	617	—	—	677
Foreign	60	—	—	—	60
Investments at NAV	—	—	—	7,640	7,640
Total investments	\$ 2,396	\$ 1,398	\$ —	\$ 7,640	\$ 11,434

The fair values of the Plan's assets at December 31, 2023, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 208	\$ 23	\$ —	\$ —	\$ 231
Fixed income securities:					
U.S. government	—	110	—	—	110
U.S. government agencies	—	175	—	—	175
U.S. corporate	—	338	—	—	338
Foreign	—	28	—	—	28
Common and preferred stocks:					
U.S.	979	—	—	—	979
Foreign	595	—	—	—	595
Funds:					
Fixed income	127	—	—	—	127
Equities	94	673	—	—	767
Foreign	54	—	—	—	54
Investments at NAV	—	—	—	7,170	7,170
Total investments	\$ 2,057	\$ 1,347	\$ —	\$ 7,170	\$ 10,574

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2024 or 2023.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2024, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,919	\$ 142	Monthly to annually	30–90 days
Private partnerships (b)	3,721	1,323		
	<u>\$ 7,640</u>	<u>\$ 1,465</u>		

At December 31, 2023, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,693	\$ 270	Monthly to annually	30–90 days
Private partnerships (b)	3,477	1,453		
	<u>\$ 7,170</u>	<u>\$ 1,723</u>		

(a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry "lockup" restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

(b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan's ownership interest in partners' capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2025.

Other postretirement benefits:

Obligations and funded status: A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

	2024	2023
Change in projected benefit obligation:		
Benefit obligation at beginning of year	\$ 869	\$ 867
Service cost	4	4
Interest cost	45	48
Plan participants contributions	44	42
Amendments	—	2
Medicare subsidy	9	3
Actuarial loss	26	10
Benefits paid	(110)	(107)
Estimated benefit obligation at end of year	<u>\$ 887</u>	<u>\$ 869</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ —	\$ —
Employer contributions	66	65
Plan participants contributions	44	42
Benefits paid	(110)	(107)
Fair value of plan assets at end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status of the plan	<u>\$ (887)</u>	<u>\$ (869)</u>

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2024	2023
Current liabilities	\$ (61)	\$ (57)
Noncurrent liabilities	(826)	(812)
Net amount recognized	<u>\$ (887)</u>	<u>\$ (869)</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2024		2023
Service cost	\$ 4	\$	4
Interest cost	45		48
Amortization of:			
Unrecognized prior service benefit	1		1
Unrecognized net actuarial loss (gain)	1		(1)
Net periodic benefit cost for other postretirement benefits	<u>\$ 51</u>	<u>\$</u>	<u>52</u>

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts: Years ending December 31:

2025	\$	5
2026		5
2027		5
2028		5
2029		5
2030–2034		25

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50 percent.

Pension and postretirement benefits:

Assumptions: Weighted average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2024	2023	2024	2023
Discount rate	5.86%	5.43%	5.74%	5.42%
Rate of compensation increase	3.69%	3.67%	—%	—%

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

Weighted-average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2024	2023	2024	2023
Discount rate	5.43%	5.77%	5.42%	5.68%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.67%	3.70%	N/A	N/A

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

Cash flows:

Contributions: The Clinic expects to contribute \$271 to its pension plans in 2025.

Estimated future benefit payments: The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2025	\$ 597	\$ 63
2026	560	65
2027	568	66
2028	570	67
2029	579	68
2030-2034	3,018	345

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was \$151 and \$142 for 2024 and 2023, respectively.

Note 17. General and Professional Liability Insurance

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 17. General and Professional Liability Insurance (Continued)

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was \$177 and \$164 at December 31, 2024 and 2023, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Activity in the liability is summarized as follows for the years ended December 31:

	2024	2023
Balance, beginning of year	\$ 164	\$ 159
Incurred related to captive insurance company liability:		
Current year	40	35
Prior years	15	20
Total incurred	55	55
Paid related to captive insurance company liability:		
Current year	—	(6)
Prior years	(60)	(40)
Total paid	(60)	(46)
Net change in self-insurance liability	18	(4)
Balance, end of year	\$ 177	\$ 164

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities

At December 31, other receivables consisted of the following:

	2024	2023
Pledges receivable	\$ 245	\$ 325
Grants receivable	160	173
Rebates receivable	85	73
Pharmacy receivable	60	74
Interest receivable	40	40
Royalty receivable	12	11
Other tax receivable	6	5
Other	99	86
Total other receivables	\$ 707	\$ 787

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other current assets consisted of the following:

	2024	2023
Inventories	\$ 253	\$ 234
Prepaid expenses	173	148
Other	30	9
Total other current assets	<u>\$ 456</u>	<u>\$ 391</u>

At December 31, other long-term assets consisted of the following:

	2024	2023
Pension asset	\$ 2,993	\$ 1,814
Trust receivables	346	218
Pledges receivable	341	346
Technology-based ventures	295	268
Oil and gas interests	254	259
Operating lease right-of-use asset	136	122
Notes receivable	78	69
Prepaid maintenance	76	79
Long-term portion of deferred tax asset	8	4
Investments in unconsolidated entities	2	164
Other	85	85
Total other long-term assets	<u>\$ 4,614</u>	<u>\$ 3,428</u>

At December 31, other current liabilities consisted of the following:

	2024	2023
Current maturities of long-term debt	\$ 105	\$ 18
Other taxes	103	92
Current portion of professional and general liability	58	49
Current portion of long-term disability	56	50
Oil and gas liability	36	51
Short-term disability	33	34
Refunds/recoupments	30	23
Real estate tax accrual	27	28
Operating lease liability	26	22
Accrued interest	21	22
Medicare settlements liability	21	12
Current portion of workers' compensation liability	13	12
Finance lease liability	8	9
Other	92	69
Total other current liabilities	<u>\$ 629</u>	<u>\$ 491</u>

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other long-term liabilities consisted of the following:

	2024	2023
Deferred compensation	\$ 1,317	\$ 1,129
Long-term disability	270	246
Operating lease liability	138	127
Professional and general liability	119	115
Electronic medical record	90	96
Retirement community obligations	88	92
Gift annuities	72	67
Financing obligations	59	60
Asset retirement obligation	55	48
Trust obligations	49	47
Workers' compensation liability	35	32
Finance lease liability	29	27
Contract deposit	25	25
Deferred gain	18	126
Other	71	66
Total other long-term liabilities	<u>\$ 2,435</u>	<u>\$ 2,303</u>

Note 19. Other Revenue

For the years ended December 31, other revenue consisted of the following:

	2024	2023
Retail pharmacy sales	\$ 660	\$ 530
Royalties	191	120
Retail stores	86	80
Oil and gas producing activities	83	75
Graduate medical and other education revenue	61	53
Technology commercialization, health information, and medical products	46	43
Cafeteria revenue	41	37
Other	283	262
Total other revenue	<u>\$ 1,451</u>	<u>\$ 1,200</u>

Note 20. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2024 is \$5,756 all of which is expected to be expended over the next three to five years. Included in this is the \$5 billion initiative for the Rochester, Minnesota campus project which includes five new buildings, and technology and infrastructure investments.

Note 20. Commitments and Contingencies (Continued)

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

Supplementary Information

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF AGRICULTURE									
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	S005163	Pennsylvania State University	S005163		\$72,194	\$72,194	RESEARCH AND DEVELOPMENT	\$490,180,429
TOTAL DEPARTMENT OF AGRICULTURE						\$72,194			
DEPARTMENT OF DEFENSE									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	BMT CTN 1702	National Marrow Donor Program	BMT CTN 1702		\$3,146	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	BMT CTN 1703/1801	National Marrow Donor Program	BMT CTN 1703/1801		\$13,629	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	HR0011-24-C-0332				\$851,193	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2007			\$354,586	\$998,542	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017				\$1,254,806	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2019				\$793,982	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-22-C-2019				\$624,690	\$4,539,988	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	FA864923P0921	Perfusion Medical, Inc.	FA864923P0921		\$22,500	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0100				\$215,868	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0110			\$110,000	\$444,828	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0234				\$440,656	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0298				\$106,379	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0328				\$196,869	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0448	University of Minnesota	HT9425-23-1-0448		\$26,110	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0485		HT9425-23-1-0485		\$231,805	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0488	Boston Scientific Corporation			\$1,702,283	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0681	Targepeutics, Inc.	HT9425-23-1-0681		\$168,667	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0752				\$246,556	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0754				\$92,375	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0900	University of Alabama at Birmingham	HT9425-23-1-0900		\$80,675	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0980	University of Pennsylvania	HT9425-23-1-0980		\$26,369	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0988	TILT Biotherapeutics Oy	HT9425-23-1-0988		\$97,292	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-1079			\$54,716	\$420,047	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-2-0026				\$483,735	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-C0067	Zymeron Corporation	HT9425-23-C0067		\$388,282	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0065				\$125,004	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0154				\$234,306	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0155				\$153,515	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0208				\$83,362	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0232				\$10,146	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0298				\$52,355	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0357				\$60,005	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0609				\$188,973	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0619				\$54,896	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0622				\$137,795	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0826				\$31	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0906				\$19,583	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0928				\$8,810	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1100				\$39,027	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1101				\$28,769	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1104				\$10,971	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1105				\$1,835	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-0317	Cedars Sinai Medical Center	W81XWH-0317		\$103,459	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0115				\$99,678	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0292				\$562,109	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0293				\$500,862	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0705	University of Alabama at Birmingham	W81XWH-15-1-0705		\$29,790	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0265				\$213,570	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0266				\$376,192	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0268				\$272,816	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0269				\$317,781	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0644	Massachusetts Eye & Ear	W81XWH-17-1-0644		\$1,424	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0073	University of Pittsburgh	W81XWH-17-2-0073		\$2,995	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0563				\$608,281	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0564				\$54,600	\$725,640	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0577	University of Minnesota	W81XWH-18-1-0577		\$14,719	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0652				\$3,139	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0760				\$24,945	\$84,994	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0021				\$127,299	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534				\$437,821	\$1,670,387	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0583				\$150,545	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0727	University of California Davis	W81XWH-19-1-0727		\$425	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0214				\$47,767	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0215				\$26,237	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0262				\$29,166	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0514				\$43,139	\$200,428	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0524	Prytime Medical Devices, Inc.	W81XWH-20-1-0524		\$151,187	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0570	Baylor University	W81XWH-20-1-0570		\$13,550	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0662				\$165,492	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0750	Cleveland Clinic Foundation	W81XWH-20-1-0750		\$385,926	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0752				\$183,568	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0886				\$43	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0923				\$36,445	\$99,536	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-C-0104	Treadmetrix	W81XWH-20-C-0104		\$30,704	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0063				\$80,527	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0121	Prytime Medical Devices, Inc.	W81XWH-21-1-0121		\$241,398	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0182				\$4,556	\$4,556	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0405				\$229,655	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0428				\$73,349	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0475	Children's Hospital of Pittsburgh			\$226,428	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0480		W81XWH-21-1-0480		\$168,470	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0489			\$217,833	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0490			\$30,499	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0624			\$126,958	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0678			\$310,159	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0704			\$237,403	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0705			\$77,729	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0706			\$73,591	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0726	University of Minnesota	W81XWH-21-1-0726	\$4,150	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0798			\$200,988	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0827	Cure HHT Foundation	W81XWH-21-1-0827	\$33,904	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0867			\$22,142	\$175,216	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0888			\$272,230	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0036			\$42,006	\$207,382	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-9-0014	University of Pittsburgh	W81XWH-21-9-0014	\$275,088	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0201	University of Iowa	W81XWH-22-1-0201	\$55,703	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0245			\$1,100,924	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0288			\$434,054	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0289			\$68,108	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0313			\$296,686	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0634			\$280,840	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0670			\$33,545	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0860			\$305,091	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0917			\$370,693	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0968			\$62,816	\$1,218,579	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0969			\$147,760	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0971	Georgia College & State University	W81XWH-22-1-0971	\$15,354	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0999	Mount Sinai Medical Center	W81XWH-22-1-0999	\$4,713	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-2-0020	Sloan-Kettering Institute for Cancer Research	W81XWH-22-2-0020	\$94,526	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-3-0001	University of Alabama at Birmingham	W81XWH-22-3-0001	\$14,110	\$22,265,176	RESEARCH AND DEVELOPMENT	\$490,180,429	
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH SERVICES	12.750	HU00011920072	Henry M. Jackson Foundation	HU00011920072	\$157,281	\$157,281	RESEARCH AND DEVELOPMENT	\$490,180,429	
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	140D0422C0053	Luna Innovations , Inc.	140D0422C0053	\$190,662	\$190,662	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	36C26223C0234			\$81,805	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	6973GH-23-T-00009			\$48,581	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	75F40120C00093	International Consulting Association	75F40120C00093	\$40,109	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	DE-AC05-76RL01830	Battelle Memorial Institute	DE-AC05-76RL01830	\$117,195	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	FA864923P0923	Perfusion Medical, Inc.	FA864923P0923	\$22,500	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	FA864924P0552	Perfusion Medical, Inc.	FA864924P0552	\$14,625	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	
CONTRACT	12.RD	FA8650-19-C-6979			\$160,563	\$1,501,731	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	H98230-13-D-0123			\$250	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429	

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CONTRACT	12.RD	H98230-18-D-0024			\$137,889	\$6,247,800	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	H98230-22-C-0095				\$1,273,687	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	H98230-24-C-0064			\$60,000	\$652,874	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	HT9425-24C-0010	InnoVital Systems, Inc.	HT9425-24C-0010		\$35,558	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	MTEC 2020-625				\$519,375	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
			Wake Forest University Health Science						
CONTRACT	12.RD	MTEC-23-04-AFIRM		MTEC-23-04-AFIRM		\$94,143	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	W81XWH-15-9-001	University of Pittsburgh	W81XWH-15-9-001		\$23,895	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	W81XWH-17-C-0029	The Geneva Foundation	W81XWH-17-C-0029		\$103,121	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	W81XWH-18-2-0076	Dartmouth College	W81XWH-18-2-0076		\$9,791	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	12.RD	W81XWH-20-1-0930	University of New Mexico	W81XWH-20-1-0930		\$70,936	\$10,857,976	RESEARCH AND DEVELOPMENT	\$490,180,429
TOTAL DEPARTMENT OF DEFENSE					\$1,704,831	\$38,011,083			
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT									
			Supportive Housing For The Elderly						
SUPPORTIVE HOUSING FOR THE ELDERLY	14.157					\$141,205	\$141,205	N/A	\$0
			Section 8 Housing Choice Vouchers						
SECTION 8 HOUSING CHOICE VOUCHERS	14.871					\$55,175	\$55,175	HOUSING VOUCHER CLUSTER	\$55,175
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT						\$196,380			
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575		Crime Victim Assistance			\$26,008	\$26,008	N/A	\$0
TOTAL DEPARTMENT OF JUSTICE						\$26,008			
DEPARTMENT OF THE TREASURY									
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	University of Wisconsin-Madison	435100-G23		\$216,133	\$2,801,472	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	Arizona State Board of Nursing	ARS 36-1803		\$426,110	\$2,801,472	N/A	\$0
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	Arizona State Board of Nursing	HB2691 ARS36-1803		\$2,159,229	\$2,801,472	N/A	\$0
TOTAL DEPARTMENT OF THE TREASURY						\$2,801,472			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
			Center for Applied Space Technology, Inc.						
SCIENCE	43.001	80NSS22K0563		80NSS22K0563		\$39,627	\$257,528	RESEARCH AND DEVELOPMENT	\$490,180,429
SCIENCE	43.001	80NSS20K0116				\$4,422	\$257,528	RESEARCH AND DEVELOPMENT	\$490,180,429
SCIENCE	43.001	80NSS20K1139				\$7,009	\$257,528	RESEARCH AND DEVELOPMENT	\$490,180,429
SCIENCE	43.001	80NSS21K0299				\$206,470	\$257,528	RESEARCH AND DEVELOPMENT	\$490,180,429
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						\$257,528			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	NSF #2152869	Texas A&M University	NSF #2152869		\$84,971	\$128,773	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ENGINEERING	47.041	NSF #2229279	Arizona State University	NSF #2229279		\$43,802	\$128,773	RESEARCH AND DEVELOPMENT	\$490,180,429
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF #10				\$18,656	\$57,045	RESEARCH AND DEVELOPMENT	\$490,180,429
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 2108060	University of North Florida	NSF 2108060		\$8,195	\$57,045	RESEARCH AND DEVELOPMENT	\$490,180,429
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 2113360				\$30,194	\$57,045	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF #2200269	Georgia Institute of Technology	NSF #2200269		\$16,961	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF #2419319				\$16,684	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1624615				\$7,648	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1901046	Purdue University	NSF 1901046		\$69,441	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2002540	University Illinois-Urbana Champaign	NSF 2002540		\$34,988	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2041339			\$40,414	\$213,067	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2123900				\$170,929	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2200058	Oxalo Therapeutics, Inc.	NSF 2200058		\$82,676	\$612,394	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOLOGICAL SCIENCES	47.074	NSF 23494	Iowa State University	NSF 23494		\$14,781	\$38,509	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOLOGICAL SCIENCES	47.074	NSF1938128	Drexel University College of Medicine	NSF1938128		\$23,728	\$38,509	RESEARCH AND DEVELOPMENT	\$490,180,429
STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES)	47.076	NSF-GRFP21				\$61,935	\$61,935	RESEARCH AND DEVELOPMENT	\$490,180,429
NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS	47.084	NSF #2112172	Rush River Research Corp.	NSF #2112172		\$53,875	\$87,496	RESEARCH AND DEVELOPMENT	\$490,180,429
NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS	47.084	NSF #2328351	Montana State University	NSF #2328351		\$33,621	\$87,496	RESEARCH AND DEVELOPMENT	\$490,180,429
TOTAL NATIONAL SCIENCE FOUNDATION					\$40,414	\$986,152			
DEPARTMENT OF VETERANS AFFAIRS									
CONTRACT	64.RD	IPA AGREEMENT				\$127,289	\$171,697	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	64.RD	IPA AGREEMENT - KAUFMAN				\$5,853	\$171,697	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	64.RD	IPA AGREEMENT - WANG				\$38,555	\$171,697	RESEARCH AND DEVELOPMENT	\$490,180,429
TOTAL DEPARTMENT OF VETERANS AFFAIRS						\$171,697			
DEPARTMENT OF EDUCATION									
FEDERAL PELL GRANT PROGRAM	84.063	PELL #1				\$57,320	\$57,320	STUDENT FINANCIAL ASSISTANCE	\$17,775,672
FEDERAL DIRECT STUDENT LOANS	84.268	Federal Direct Student Loans				\$17,718,352	\$17,718,352	STUDENT FINANCIAL ASSISTANCE	\$17,775,672
TOTAL DEPARTMENT OF EDUCATION						\$17,775,672			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
TRANS-NIH RESEARCH SUPPORT	93.310	AG75941	University of Connecticut	AG75941		\$279,509	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	AG79754	University of Minnesota	AG79754		\$523,138	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TRANS-NIH RESEARCH SUPPORT	93.310	AG79758	Sanford-Burnham Medical	AG79758		\$67,937	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	AG79779	Johns Hopkins University	AG79779		\$339,383	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	CA268091	University of Michigan	CA268091		\$16,523	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	CA268103				\$453,023	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	CA268108	University of Pittsburgh	CA268108		\$44,248	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	CA275669				\$248,863	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	DK112326				\$875,655	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	OD023121				\$24,765,389	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	OD034496				\$223,816	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	OD23121				\$2,050,612	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
			Massachusetts General Hospital						
TRANS-NIH RESEARCH SUPPORT	93.310	OD32701		OD32701		\$222,638	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	OD38392				\$33,756	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANS-NIH RESEARCH SUPPORT	93.310	TR02471				\$427	\$30,144,917	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR00237				\$12,667	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002377			\$43,669	\$7,975,505	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002379				\$1,602,679	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02062				\$586	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02380				\$650,698	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02743			\$27,710	\$283,581	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR04432	Vanderbilt University Medical Center	TR04432		\$61,643	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR04626	Children's Hospital of Philadelphia	TR04626		\$78,380	\$10,665,739	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL151662			\$199,050	\$478,769	\$751,934	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL158287	University of Arizona	HL158287		-\$5,144	\$751,934	RESEARCH AND DEVELOPMENT	\$490,180,429
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL158287	University of Miami	HL158287		\$278,309	\$751,934	RESEARCH AND DEVELOPMENT	\$490,180,429
CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION	93.068	DP06703				\$816,489	\$816,489	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	DD01155	Great Lakes Hemo Foundation	DD01155		\$856	\$24,906	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	NU27DD000020	Great Lakes Hemo Foundation	NU27DD000020		\$24,050	\$24,906	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	NH23IP922656	American Society Clinical Oncology	NH23IP922656		\$107,349	\$107,349	RESEARCH AND DEVELOPMENT	\$490,180,429
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	NU50CK000628	Minnesota Department of Health	NU50CK000628		\$116,120	\$116,120	RESEARCH AND DEVELOPMENT	\$490,180,429
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	75F40122C00183	Univ of Missouri - Kansas City	75F40122C00183		\$14,122	\$14,122	RESEARCH AND DEVELOPMENT	\$490,180,429
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	HRSA-22-145	Cure HHT Foundation	HRSA-22-145		\$131,352	\$159,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24052	Great Lakes Hemo Foundation	MC24052		\$27,949	\$159,301	RESEARCH AND DEVELOPMENT	\$490,180,429
ENVIRONMENTAL HEALTH	93.113	ES36131	University of Florida	ES36131		\$83,650	\$83,650	RESEARCH AND DEVELOPMENT	\$490,180,429
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE031424			\$66,173	\$151,370	\$1,418,847	RESEARCH AND DEVELOPMENT	\$490,180,429
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29322			\$124,819	\$612,493	\$1,418,847	RESEARCH AND DEVELOPMENT	\$490,180,429
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29754	University of North Carolina at Chapel Hill	DE29754		\$52,707	\$1,418,847	RESEARCH AND DEVELOPMENT	\$490,180,429
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29832			\$113,604	\$526,024	\$1,418,847	RESEARCH AND DEVELOPMENT	\$490,180,429
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE30596	Mount Sinai School of Medicine	DE30596		\$66,063	\$1,418,847	RESEARCH AND DEVELOPMENT	\$490,180,429
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE31296	University of Michigan	DE31296		\$10,190	\$1,418,847	RESEARCH AND DEVELOPMENT	\$490,180,429
GRANTS TO INCREASE ORGAN DONATION	93.134	HS33878	University of Kansas Medical Center	HS33878		\$19,003	\$19,003	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG06379			\$84,557	\$1,357,325	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG06834	The Broad Institute, Inc.	HG06834		\$93,367	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG09650	University of North Carolina at Chapel Hill	HG09650		\$97,444	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG09668	Case Western Reserve University	HG09668		\$41,779	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG10166	Cincinnati Children's Hospital	HG10166		\$55,584	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG11461			\$386,969	\$900,613	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG11710				\$608,212	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG11899				\$603,915	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG12402	University of North Carolina at Chapel Hill	HG12402		\$141,857	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG12748	University of Texas Health at Houston	HG12748		\$26,029	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG13341				\$12,647	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG13425			\$90,708	\$402,172	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
HUMAN GENOME RESEARCH	93.172	HG13718				\$8,639	\$4,349,583	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC021115			\$10,209	\$33,732	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC12519				\$706,929	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC14942				\$725,386	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC18920	Ohio State University	DC18920		\$69,420	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19114			\$24,939	\$696,783	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19402	Michigan State University	DC19402		\$99,402	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC20175	Oregon Health & Science University	DC20175		\$9,270	\$2,340,922	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010875				\$749,120	\$1,975,454	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT09665	Minnesota HealthSolutions Corp	AT09665		\$11,854	\$1,975,454	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12185				\$916,778	\$1,975,454	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12307	University of Minnesota	AT12307		\$297,702	\$1,975,454	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS028475				\$117,043	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26379	University of Minnesota	HS26379		\$12,813	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28583	University of Minnesota	HS28583		\$24,353	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28639			\$11,962	\$585,284	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29460	University of Minnesota	HS29460		\$42,867	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29744	University of Minnesota	HS29744		\$34,632	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29774				\$453,757	\$1,270,749	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134808				\$62,302	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134885				\$3,859	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL146114				\$694,013	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160368	REMastered Sleep LLC	HL160368		\$74,974	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160619				\$909,433	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL162131	Minnesota HealthSolutions Corp	HL162131		\$57,839	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL168173	Binghamton University	HL168173		\$45,560	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL65176				\$22,076	\$1,870,056	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH113700				\$58	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114967	Research Foundation for Mental Hygiene, Inc.	MH114967		\$28,714	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121191	Harvard School - Public Health	MH121191		\$106,053	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121542	Johns Hopkins University	MH121542		\$16,377	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121924				\$103,117	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH122258			\$35,259	\$245,495	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124655			\$44,502	\$433,060	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH125935	University of Washington	MH125935		\$100,889	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH126700	University of California San Diego	MH126700		\$61,038	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH128296				\$145,384	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129278	Advanced MRI Technologies, LLC	MH129278		\$37,045	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129301	Yale University	MH129301		\$185,507	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131254				\$53,927	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131623			\$149,365	\$426,554	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH132746	Arizona State University	MH132746		\$8,693	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH136069	Yale University	MH136069		\$62,159	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH137213				\$49,385	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
MENTAL HEALTH RESEARCH GRANTS	93.242	MH98062	University California San Francisco	MH98062		\$78,846	\$2,142,301	RESEARCH AND DEVELOPMENT	\$490,180,429
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	MDH220856	Minnesota Department of Health	MDH220856		\$107,829	\$107,829	N/A	\$0
ALCOHOL RESEARCH PROGRAMS	93.273	AA20735	University of Nebraska Medical Center	AA20735		\$294,926	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA21171				\$307,593	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA26886				\$46,871	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA26887				\$34,529	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA26974				\$380,008	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA27179			\$35,127	\$113,111	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA27486				\$144,971	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA28050				\$122,123	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA28968				\$21,088	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA29258				\$371,195	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA30184				\$71,698	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA30273				\$461,789	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
ALCOHOL RESEARCH PROGRAMS	93.273	AA31257				\$406,128	\$2,776,030	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	CA261067	NYU Langone Medical Center	CA261067		\$4,600	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	CA278594			\$21,346	\$1,400,635	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA40316	Hennepin Healthcare Research Institute	DA40316		\$102,934	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA42492				\$340,825	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55017				\$189,933	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55167				\$67,190	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55848				\$171,794	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA56469			\$166,458	\$330,165	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA57928				\$514,557	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	NS1133515			\$251,230	\$648,040	\$3,770,673	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB001981				\$313,158	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17095				\$527,840	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17197				\$453,201	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19403			\$240,684	\$370,554	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26284	University of Southern California	EB26284		\$119	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27100	Stanford University	EB27100		\$12,372	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28590				\$246,293	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28936				\$351,493	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB29242	Montana State University	EB29242		\$84,218	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB30529			\$47,917	\$806,945	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31040	University Illinois-Urbana Champaign	EB31040		\$54,567	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31790				\$518,009	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31992	Massachusetts Institute of Technology	EB31992		\$116,430	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB32958	University of Southern California	EB32958		\$7,240	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33008				\$575,124	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33356	Pennsylvania State University	EB33356		\$14,563	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33725	Health Discovery Labs	EB33725		\$6,740	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB34346				\$45,625	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB35231				\$32,694	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB35403	Arizona State University	EB35403		\$138,078	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB35553			\$9,734	\$223,106	\$4,898,369	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD012388	Northern Arizona University	MD012388		\$23,368	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD12388	Northern Arizona University	MD12388		\$20	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD16230				\$118,186	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17217				\$195,961	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17342	University of Minnesota	MD17342		\$1,727,169	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17690	Moorhouse School of Medicine	MD17690		\$50,765	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19360				\$797	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19549	Minnesota HealthSolutions Corp	MD19549		\$7,216	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19644				\$73,615	\$2,197,097	RESEARCH AND DEVELOPMENT	\$490,180,429
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318	NU3HCK000006	Vanderbilt University Medical Center	NU3HCK000006		\$38,586	\$38,586	RESEARCH AND DEVELOPMENT	\$490,180,429
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	93.323	NU50CK00058	Minnesota Department of Health	NU50CK00058		\$5,389	\$5,389	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD20166	Iowa State University	OD20166		\$46,606	\$282,303	RESEARCH AND DEVELOPMENT	\$490,180,429
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD35424				\$235,697	\$282,303	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233033				\$900,253	\$1,697,659	RESEARCH AND DEVELOPMENT	\$490,180,429
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233046	University of North Carolina at Chapel Hill	CA233046		\$130,120	\$1,697,659	RESEARCH AND DEVELOPMENT	\$490,180,429
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA246568			\$82,025	\$531,461	\$1,697,659	RESEARCH AND DEVELOPMENT	\$490,180,429
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA252973	University of New Mexico	CA252973		\$135,825	\$1,697,659	RESEARCH AND DEVELOPMENT	\$490,180,429
PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE	93.354	NU90TP92	Minnesota Department of Health	NU90TP92		\$7,573	\$7,573	RESEARCH AND DEVELOPMENT	\$490,180,429
NURSING RESEARCH	93.361	NR020362				\$199,589	\$1,307,925	RESEARCH AND DEVELOPMENT	\$490,180,429
NURSING RESEARCH	93.361	NR16433				\$7,055	\$1,307,925	RESEARCH AND DEVELOPMENT	\$490,180,429
NURSING RESEARCH	93.361	NR18832				\$905,553	\$1,307,925	RESEARCH AND DEVELOPMENT	\$490,180,429
NURSING RESEARCH	93.361	NR20362			\$35,387	\$195,728	\$1,307,925	RESEARCH AND DEVELOPMENT	\$490,180,429
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)	93.384	D24AC00358	University Illinois-Urbana Champaign	D24AC00358		\$97,191	\$97,191	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA132878				\$311,261	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA167551	University of Melbourne	CA167551		\$167,841	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA195568			\$919,545	\$2,781,701	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207084				\$327	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217889				\$266,467	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224917			\$50,556	\$74,508	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225662				\$239,917	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA230712				\$37,556	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233432	Kaiser Foundation Research Ins	CA233432		\$27,742	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233610			\$133,395	\$875,057	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233700				\$38,924	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA234943				\$62,211	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235026				\$127,391	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237398			\$757	\$265,879	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237607			\$252,652	\$1,140,247	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA243483	Baylor College of Medicine	CA243483		\$52,415	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA244670	University of Washington St. Jude Children's Research Hospital	CA244670		\$106,886	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA246510		CA246510		\$68,998	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247283	Johns Hopkins University	CA247283		\$8,551	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247642	Alaska Native Tribal Health Consortium	CA247642		\$14,454	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA248288			\$183,562	\$650,520	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA252060				\$484,526	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253187				\$928,909	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254844	Carina Medical, LLC	CA254844		\$58,267	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254951				\$677,353	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA255082	University of Washington	CA255082		\$132,599	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
			Washington University in St. Louis	CA256810		\$126,378	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$155,116	\$230,160	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of Vermont	CA258119		\$4,110	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$393,851	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of Wisconsin-Madison	CA26211		\$59,343	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			Tufts Medical Center	CA262265		\$109,625	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$85,452	\$964,574	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$353,023	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$30,000	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$667,225	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			U.T. Southwestern Medical Center	CA265967		\$34,570	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			Collinge and Associates, Inc	CA268678		\$11,214	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$180,001	\$490,073	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			NYU Grossman School of Medicine	CA269617		\$96,017	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			Ohio State University	CA269832		\$200,775	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$138,045	\$747,499	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$104,975	\$535,751	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$78,730	\$489,465	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$308,229	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$463,166	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$389,440	\$598,324	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$101,244	\$648,772	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$542,954	\$945,808	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			Arizona State University	CA275085		\$77,316	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$500,517	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$19,138	\$163,745	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of Michigan	CA288625		\$3,328	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$59,179	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$6	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
			Northwestern University	CA292771		\$2,651	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$153,975	\$19,069,176	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$247,349	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
			Partners Health Care Research Management	CA184102		\$8,530	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
			Washington University in St. Louis	CA196171		\$579,554	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$160,576	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$357,701	\$826,095	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$304,584	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of Wisconsin-Madison	CA223481		\$18,637	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
						\$103,706	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
					\$132,537	\$672,922	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237659	University of Pennsylvania	CA237659		\$24,443	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA238926				\$366,323	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239164				\$284,225	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239200			\$100,663	\$550,781	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239548				\$434,644	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241020				\$71,388	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241164				\$550,307	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246665	Public Health Institute	CA246665		\$243	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246704	Northwestern University	CA246704		\$28,868	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251065	University of Iowa	CA251065		\$103,676	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251065				\$17,647	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251801			\$193,658	\$654,277	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251923				\$15,959	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256648				\$685	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256969	Fred Hutchinson Cancer Research Center	CA256969		\$83,722	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256969	University California San Francisco	CA256969		-\$577	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA257558			\$227,023	\$646,046	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA258465			\$249,222	\$798,029	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA260259			\$11,746	\$604,796	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA264992	MD Anderson Cancer Center	CA264992		\$320,651	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA264992	St. Joseph's Hospital and Medical Center	CA264992		-\$80,719	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA265879	Rhode Island Hospital	CA265879		\$132,664	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA265945	University of Minnesota	CA265945		\$19,080	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA268452	Rush River Research Corp.	CA268452		\$62,686	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271402	Washington University in St. Louis	CA271402		\$32,696	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271410			\$85,620	\$1,385,185	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA272271	University Illinois-Urbana Champaign	CA272271		\$38,382	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA272628			\$69,000	\$537,882	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA274496				\$606,108	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA276690	U.T. Southwestern Medical Center	CA276690		\$258,586	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA279629	Indiana University	CA279629		\$136,480	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA279916				\$123,893	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA279984	University of California Los Angeles	CA279984		\$545	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA280151	Case Western Reserve University	CA280151		\$2,585	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA283663				\$8,276	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA284268	Johns Hopkins University	CA284268		\$231,038	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA286127	Washington University in St. Louis	CA286127		\$116,599	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA292129	University of Arizona	CA292129		\$5,388	\$12,095,440	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	A022104	Public Health Institute	A022104		\$9,878	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	A082101	Alliance for Clinical Trials in Oncology	A082101		\$15,317	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	A11104	Brigham & Women's Hospital	A11104		\$683	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	A151804	Alliance for Clinical Trials in Oncology	A151804		\$11,709	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA108671	Icahn School of Medicine	CA108671		\$421,688	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA13650	Eastern Cooperative Oncology Group	CA13650		\$62	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180790	Duke Clinical Research Institute	CA180790		\$7	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180790	Alliance for Clinical Trials in Oncology	CA180790		\$37,007	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180820	ECOG Research and Education Foundation, Inc.	CA180820		\$51,590	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180821	Brigham & Women's Hospital	CA180821		\$951,711	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180868	NRG Oncology Foundation, Inc.	CA180868		\$20,286	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180882			\$672,568	\$9,225,382	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180886	Children's Hospital of Philadelphia	CA180886		\$33,510	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180886	Public Health Institute	CA180886		\$8,391	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA180888	Oregon Health & Science University	CA180888		\$26,290	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA181255	George Washington University	CA181255		\$517,895	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA186686	National Cancer Institute	CA186686		\$1,067	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA186709	Dana-Farber Cancer Institute	CA186709		\$1,186,587	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA203430	Perspective Therapeutics, Inc	CA203430		\$92,720	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA205406	Dana-Farber Cancer Institute	CA205406		\$60,199	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA207183			\$2,467	\$173,152	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA207386				\$3,937	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA217591	Syntrix Biosystems, Inc.	CA217591		\$78,540	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA221461	VYRIAD	CA221461		\$7,527	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA225996				\$406,390	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA227092	Fred Hutchinson Cancer Research Center	CA227092		\$29,235	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA228823	Public Health Institute	CA228823		\$25,823	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA229100			\$282,987	\$779,521	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA229560				\$107,739	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA232760				\$711,008	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	CA233024	VYRIAD	CA233024		\$52,892	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA233332	Sloan-Kettering Institute for Cancer Research	CA233332		\$40,627	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA233878	Northwestern University	CA233878		\$115,500	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA235726	University of Alabama at Birmingham	CA235726		\$19,925	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA238946	Ohio State University	CA238946		\$6,597	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA243078	Translational Genomics Research Institute	CA243078		-\$5,030	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA243078	University of Wisconsin-Madison	CA243078		\$48,352	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA248064				\$272,214	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA248147			\$12,341	\$556,314	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA249929	University of Pennsylvania	CA249929		\$60,487	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA251910	Sanford-Burnham Medical	CA251910		\$2,079	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA25224	National Cancer Institute	CA25224		\$1,587	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA255176	Louisiana State University and A&M College	CA255176		\$46,403	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA255176	University of Louisiana Monroe	CA255176		\$5,079	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA256927				\$312,065	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA258239				\$594,716	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA261854				\$295,665	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA262613				\$518,928	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA263003				\$175,886	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA264362			\$230,834	\$981,326	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA266344			\$138,811	\$639,114	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA266999				\$161,123	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA267098				\$274,839	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA269384				\$394,386	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA270380				\$346,403	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA271431			\$338,586	\$772,625	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA272064	Modulation Therapeutics	CA272064		\$61,383	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA272257			\$310,405	\$801,202	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA272426				\$749,042	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA272496				\$480,764	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA274985				\$694,665	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA275560	Targepeutics, Inc.	CA275560		\$30,504	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA275870				\$463,214	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA276005				\$660,525	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA276313				\$435,475	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA276851			\$74,996	\$638,660	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA27785	Emmyon, Inc.	CA27785		\$100,289	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA277853	Emmyon, Inc.	CA277853		\$109,521	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA278184	Trekka Therapeutics LLC	CA278184		\$146,096	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA278197	Washington University in St. Louis	CA278197		\$16,379	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	CA278293	Myosin Therapeutics	CA278293		\$189,861	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA278773				\$38,680	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA278908				\$44,569	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA280134				\$57,487	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA280999				\$422,130	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA281707	NanoValent Pharmaceutical Inc.	CA281707		\$16,684	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA282756	NYU Grossman School of Medicine	CA282756		\$312,953	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA283479				\$332,827	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA285345			\$14,238	\$271,539	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA285536				\$152,762	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA286349				\$67,501	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA286864				\$183,570	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA288753				\$3,147	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA289285				\$279,646	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA294704				\$19,767	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA84203	Massachusetts General Hospital	CA84203		\$125,342	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	CA189823	Canadian Cancer Clinical Trials Group	CCTG-NEI		\$5,008	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	ECOG 01	Frontier Science & Technology	ECOG 01		\$8,139	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	GOG 01	The Gynecologic Oncology Group	GOG 01		\$1,365	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	NCCTG 2013	North Central Cancer Treatment Group	NCCTG 2013		\$976	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER TREATMENT RESEARCH	93.395	RTOG1216	Alliance for Clinical Trials in Oncology	RTOG1216		\$47,151	\$29,653,776	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA130908				\$22,025	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA225680				\$2,093	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA233790				\$402,575	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA238720	Massachusetts Institute of Technology	CA238720		\$29,708	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA239726				\$511,693	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA240323				\$313,841	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA241123	University at Buffalo	CA241123		\$58,090	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA242023				\$306,917	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA243545				\$377,544	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA247929				\$455,421	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA248019	Case Western Reserve University	CA248019		\$13,842	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA248298				\$344,871	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA249116				\$498,001	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA250481			\$437,414	\$789,780	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA251443	University of New South Wales	CA251443		\$119,742	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	CA254849	University of Minnesota	CA254849		\$26,085	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA254961				\$370,131	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA255068				\$444,716	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
			University Illinois-Urbana Champaign	CA256481		\$77,501	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA256481			\$70,602	\$297,989	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA261925				\$357,314	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA261932				\$361,405	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA262262	University of Utah	CA262262		\$6,108	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA264048			\$74,541	\$516,356	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
			Joan & Sanford I. Weill Medical	CA265892		\$12,914	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA265892			\$255,799	\$416,764	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
			The Research Foundation SUNY	CA269075		\$178,942	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA269075				\$236,614	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA269295			\$21,293	\$303,533	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA271486				\$532,540	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA272602				\$302,772	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA273027				\$353,028	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA275669				\$490,582	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA276047							
CANCER BIOLOGY RESEARCH	93.396	CA278300	H. Lee Moffit Cancer Center & Research Institute	CA278300		\$26,133	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
			H. Lee Moffit Cancer Center & Research Institute	CA279065		-\$783	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA279065				\$13,878	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA279065	Mercy Children's Hospital	CA279065					
			Brigham & Women's Hospital	CA282451		\$263,711	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA282451				\$99,501	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA283317				\$78,981	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA284153				\$36,981	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	CA294653				\$122,456	\$10,172,295	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER BIOLOGY RESEARCH	93.396	HL145268							
CANCER CENTERS SUPPORT GRANTS	93.397	CA116201			\$358,174	\$2,646,398	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA136393			\$215,591	\$1,851,017	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083				\$7,042,486	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
			Dana-Farber Cancer Institute	CA168504		\$2,550	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA168504			\$84,418	\$2,410,601	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA186781				\$365	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA210190	University of Minnesota	CA210190					
CANCER CENTERS SUPPORT GRANTS	93.397	CA210964			\$75,000	\$499,989	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA225520	University of Oklahoma	CA225520		\$11,777	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA272170	University of Michigan	CA272170		\$98,440	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA274504			\$787,405	\$1,740,251	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
			Massachusetts Institute of Technology	CA283114		\$200,583	\$16,504,457	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CENTERS SUPPORT GRANTS	93.397	CA283114				\$71,178	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA217836				\$213,698	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA230193							

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER RESEARCH MANPOWER	93.398	CA236874				\$169,375	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA237875				\$216,887	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA250122				\$11,956	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA252044				\$323,392	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA257228				\$32,330	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA271560				\$32,570	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA273304				\$124,617	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA279652				\$46,542	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA283317				\$45,298	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA284259				\$46,152	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA287495				\$36,025	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER RESEARCH MANPOWER	93.398	CA90628				\$880,129	\$2,250,149	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CONTROL	93.399	CA189823	Alliance for Clinical Trials in Oncology	CA189823		\$1,737,344	\$1,888,052	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CONTROL	93.399	CA189823	University of Alabama at Birmingham	CA189823		\$1,127	\$1,888,052	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CONTROL	93.399	CA189955	Children's Hospital of Philadelphia	CA189955		\$228	\$1,888,052	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CONTROL	93.399	CA189955	Public Health Institute	CA189955		\$8,819	\$1,888,052	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CONTROL	93.399	CA220242				\$24,818	\$1,888,052	RESEARCH AND DEVELOPMENT	\$490,180,429
CANCER CONTROL	93.399	CA242635	University of Wisconsin-Madison	CA242635		\$115,716	\$1,888,052	RESEARCH AND DEVELOPMENT	\$490,180,429
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPHF0006	Indiana University	90DPHF0006		\$7,879	\$554,556	RESEARCH AND DEVELOPMENT	\$490,180,429
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0031				\$382,894	\$554,556	RESEARCH AND DEVELOPMENT	\$490,180,429
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90SIMS0008	University of Minnesota	90SIMS0008		\$163,783	\$554,556	RESEARCH AND DEVELOPMENT	\$490,180,429
PUBLIC HEALTH RESPONSE, FORECASTING, AND ANALYTIC CAPACITIES RELATED TO DISEASE OUTBREAKS, EPIDEMICS, AND PANDEMICS	93.823	FT000003	University of Minnesota	FT000003		\$84,329	\$84,329	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL07111				\$588,878	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107304			\$8,456	\$194,046	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117913				\$440,276	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL119795				\$9,248	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL127672	LAM Foundation	HL127672		\$3,375	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL133501			\$350,121	\$469,552	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134664				\$359,770	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134864				\$176,904	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135879				\$150	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136340				\$15,376	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136348				\$35,615	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140411			\$44,191	\$220,500	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142068				\$308,275	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142627				\$196,171	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL144529			\$94,362	\$364,059	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145121				\$57,116	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145268			\$323,168	\$788,412	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147155				\$602	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148144				\$174,782	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148339				\$380,785	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
			Case Western Reserve University	HL149409		\$18,371	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149409				\$258,298	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL150086				\$516,606	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151379				\$380,206	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL153098				\$15,587	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL153847	University of Pittsburgh	HL153847		\$4,595	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155396	Duke University	HL155396		\$182,635	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155506				\$43,846	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155834	University of Michigan	HL155834		\$72,051	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156812	Duke University	HL156812		\$76,042	\$842,269	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156855								
			NYU Grossman School of Medicine	HL157220		\$71,704	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL157220				\$686,786	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158548			\$231,939	\$507,063	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158691			\$80,153	\$728,322	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158932				\$362,571	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL159216	Indiana University	HL159216		\$33,569	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160226				\$444,001	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160273	Northwestern University	HL160273		\$285,818	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160643				\$113,588	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
			University of California Los Angeles	HL160730		\$16,381	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160730				\$891,341	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161169				\$1,049,902	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
			Beth Israel Deaconess Medical Center	HL161697		\$20,313	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161697				\$31,585	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161765	Binghamton University	HL161765		\$721,049	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161821				\$177,995	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162747				\$734,924	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162828				\$629,642	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162830				\$328,631	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164140	Vivita Technologies, Inc.	HL164140		\$71,757	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164379	Cleveland Clinic Foundation	HL164379		\$10,403	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164416			\$52,301	\$490,043	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164520				\$913,203	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165065	Northwestern University	HL165065		\$22,136	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165176			\$277,430	\$579,823	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL166140			\$17,494	\$695,526	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL166204				\$413,357	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429	

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL167811	Massachusetts Institute of Technology		\$150,975	\$341,936	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL167947		HL167947		\$69,717	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL168392	Columbia University			\$10,584	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL169268		HL168392	\$15,572	\$650,924	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL169320				\$341,408	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL170507				\$37,170	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL171023				\$144,984	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL171158	Miriam Hospital			\$6,130	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL172784		HL171158	\$35,429	\$223,904	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL173775				\$50,619	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL174785				\$270,003	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL175086				\$236,691	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL175879	University of Michigan			\$4,259	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL81753		HL175879	\$139,228	\$714,469	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84155				\$473,125	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL96812	Johns Hopkins University NYU Grossman School of Medicine			\$84,694	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL96812		HL96812		\$89,156	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL98967				\$481,449	\$22,203,016	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL105355				\$6,800	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL125177	Cleveland Clinic Foundation			\$86,971	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL126667		HL125177	\$4,373	\$224,614	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL130881			\$1,319	\$156,391	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL138998	University of North Carolina at Chapel Hill			\$23,210	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL139054		HL138998		\$35,787	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL139126	Indiana University			\$11,624	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL140177		HL139126		\$23,381	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL140486	Columbia University			\$30,329	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL141722		HL140177		\$429,008	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL142061				\$4,440	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL142093	Brigham & Women's Hospital			\$5,065	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL142269	University of Pennsylvania			\$103,165	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL142933		HL142269	\$4,043	\$382,228	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL142992	Stanford University			\$301,189	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL145265		HL142992		\$12,977	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL146002	Brigham & Women's Hospital			\$75,893	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL146705	North Dakota State University			\$123,560	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL146741		HL146705		\$222,795	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL147261	University of Michigan			\$12,781	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL148437		HL147261		\$16,103	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL151671	National Jewish Health			\$171,375	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL151865	University of Colorado			\$32,448	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL151865		HL151865					

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	HL152967			\$266,388	\$609,880	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL153026				\$4,239	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL153407				\$638,300	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL155410	Stanford University	HL155410		\$148,265	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL156812	Columbia University	HL156812		\$7,342	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL156812	Duke University	HL156812		\$309,234	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL156812	RTI International	HL156812		\$2,471,157	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL157424	National Jewish Health	HL157424		\$220,638	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL157984				\$740,584	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL158287	University of Arizona	HL158287		\$338,377	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL158507	Indiana University	HL158507		\$8,005	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL158532			\$251,988	\$741,659	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL158549				\$5,667	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL158811			\$47,542	\$486,469	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL160545				\$43,584	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL160570			\$110,154	\$623,192	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161362	University of California San Diego	HL161362		\$418,369	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161674	Cleveland Clinic Foundation	HL161674		-\$1,361	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161674			\$95,815	\$294,427	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161804	Sanford-Burnham Medical	HL161804		\$135,512	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161841	Massachusetts General Hospital	HL161841		\$531	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161847	Massachusetts General Hospital	HL161847		\$6,090,355	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL161847	NYU Grossman School of Medicine	HL161847		-\$1,007	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL162169	Shape Medical Systems, Inc.	HL162169		\$15,984	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL164901				\$172,070	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL165960	Quench Medical, Inc.	HL165960		\$35,622	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL166187				\$544,037	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL166402	University of Maryland	HL166402		\$235,157	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL167732				\$12,396	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL167796				\$281,836	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL168212				\$193,498	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL169382				\$354,817	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL169759	Oregon Health & Science University	HL169759		\$20,417	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL170802	Minnesota HealthSolutions Corp	HL170802		\$40,884	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL170961	University of Virginia	HL170961		\$294,540	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL171056			\$18,789	\$622,629	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL171245	North Dakota State University	HL171245		\$3,814	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL171915	Lundquist Institute for Biomedical Innovation at Harbor	HL171915		\$22,561	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	HL173214				\$24,844	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL174505				\$90,428	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL175907				\$36,913	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL176063				\$5,000	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL176373	Glycodots, LLC.	HL176373		\$7,416	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL56470			\$146,556	\$763,013	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL62150				\$540,959	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL88029				\$9,464	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
LUNG DISEASES RESEARCH	93.838	HL92961				\$672,260	\$21,976,313	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL112792	Northwestern University	HL112792		\$22,318	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL130724	Versiti	HL130724		\$41,401	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL138645	Mount Sinai School of Medicine	HL138645		\$6,366	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL139854				\$816,305	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL140097	Cleveland Clinic Foundation	HL140097		\$33,270	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL141112				\$339,645	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL142389	Syntrix Biosystems, Inc.	HL142389		\$212,688	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL146508				\$196,790	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147852				\$245,207	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147894	University of Washington	HL147894		\$14,807	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL153310				\$208,505	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL154385	University of Washington	HL154385		\$97,318	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL157401	University of Alabama at Birmingham	HL157401		\$36,910	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL157560	National Marrow Donor Program	HL157560		\$4,190	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL159561			\$3,162	\$58,064	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL161804	Sanford-Burnham Medical	HL161804		\$42,121	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL162729			\$49,391	\$912,154	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL166238			\$214,335	\$638,228	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL167354				\$325,465	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL171911				\$130,020	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL174922	University of Louisville Research Foundation	HL174922		\$7,172	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL176351	SanaHeal	HL176351		\$577	\$4,389,521	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR056950				\$548,954	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR077538			\$55,756	\$631,447	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078552				\$343,973	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR42527				\$139,643	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR46849				\$89,427	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55557	Brigham & Women's Hospital	AR55557		\$14,681	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55563			\$587,992	\$603,655	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56212				\$455,807	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56647				\$80,964	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR69400	Emmyon, Inc.	AR69400		\$8,258	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72597				\$10,039	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72634	University of Minnesota	AR72634		\$3,070	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73147				\$134,549	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73811				\$132,247	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74395			\$93,975	\$356,069	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74859	Neuromuscular Dynamics, LLC	AR74859		\$7,235	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75037				\$167,546	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75370				\$73,927	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76028				\$44,715	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76144	University of Pittsburgh	AR76144		\$1,135	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76312			\$184,930	\$782,608	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76339				\$522,131	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76347				\$492,623	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76568	University of Pittsburgh	AR76568		\$97,000	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77518				\$333,619	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78073	University of Michigan	AR78073		\$33,778	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78254				\$189,943	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78389	University of California Irvine	AR78389		\$29,174	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78924	Rhode Island Hospital	AR78924		\$112,900	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR79098			\$19,703	\$27,967	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR80377	Population Health Res. Institute	AR80377		\$2,095	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR80745				\$136,548	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81040	Maine Medical Center	AR81040		\$75,760	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81040	Northeastern University	AR81040		-\$3,178	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81318				\$489,341	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81382	University of Texas Health at Houston	AR81382		\$11,774	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81788	University of Michigan	AR81788		\$244,454	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81898				\$84,057	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR82084	Johns Hopkins University	AR82084		\$28,462	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR82134				\$194,752	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR82227				\$49,423	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84126				\$32,323	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84283				\$86,338	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84329				\$15,001	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84831				\$83,014	\$7,999,248	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07013				\$220,285	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07198				\$514,096	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07352				\$440,587	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK078646			\$24,958	\$131,212	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100846	University of Pennsylvania The Research Institute at Nationwide Children's Hospital	DK100846		\$17,100	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866				\$1,702	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101240	Oasis Pharmaceuticals, LLC	DK101240		\$173,948	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405				\$178,576	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106993	University of South Florida	DK106993		\$10,333	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107255				\$2,314	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107733	University of TX SW Medical Center	DK107733		\$148,874	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288	University of Texas at San Antonio	DK108288		\$15,056	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288				\$602,110	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110986	Washington University in St. Louis	DK110986		\$10,167	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110988	Duke University	DK110988		\$3,467	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111378				\$415,951	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113999				\$160,042	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114007				\$564,000	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114786	Children's Hospital of Philadelphia	DK114786		\$20,410	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575	University of North Carolina at Chapel Hill	DK115575		-\$23,823	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575				\$857,970	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116092	University of Wisconsin-Madison	DK116092		\$4,682	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116231				\$772,328	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116743	Oregon Health & Science University	DK116743		\$6,821	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117861				\$303,243	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117910				\$535,538	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118619				\$133,982	\$1,939,939	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120261	Oxalo Therapeutics, Inc.	DK120261		\$157,316	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120292				\$68,692	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120559				\$300,547	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429	

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120890	Temple University Hospital	DK120890		\$33,471	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121204				\$149,472	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121330	University of Texas Health at Houston	DK121330		\$31,084	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121766				\$106,565	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122603	JAEB Center for Health Research, Inc.	DK122603		\$18,067	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122734				\$308,731	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122948				\$282,494	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123441	Arizona State University	DK123441		\$75,274	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123549				\$437,119	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124182				\$84,041	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$200,394	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124358				\$140,597	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125243	Adva-tec, Inc.	DK125243		\$91,146	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125252				\$161,104	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125431	University of Minnesota	DK125431		\$29,466	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125495	Cedars Sinai Medical Center	DK125495		\$21,334	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125680	Johns Hopkins University	DK125680		-\$157	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125680			\$172,289	\$374,205	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125692	University of Alabama	DK125692		\$23,501	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125911	Duke University	DK125911		\$1,323	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125933	University of Minnesota	DK125933		\$10,463	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126110	University of Maryland-Baltimore	DK126110		\$207,759	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126206			\$42,503	\$583,909	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126662				\$359,773	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126691			\$125,917	\$279,420	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126827				\$420,899	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127010				\$25,453	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127064				\$125,719	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127157	University of North Carolina at Chapel Hill	DK127157		\$2,455	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127403	Cedars Sinai Medical Center	DK127403		\$7,797	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127564				\$55,149	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127978				\$510,476	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127992				\$418,410	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127998				\$298,484	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128017				\$308,749	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128552				\$235,286	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128842	University of Colorado	DK128842		\$25,299	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128844				\$67,381	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128913				\$55,663	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129191	University of Colorado	DK129191		\$9,868	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129205				\$505,872	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129208				\$167,188	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129240			\$30,094	\$438,572	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129241				\$367,991	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129259	University of Colorado	DK129259		\$26,836	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129297				\$569,818	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129315			\$267,440	\$928,524	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129564	Virginia Commonwealth University	DK129564		\$170,729	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129616	Yale University	DK129616		\$115,433	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129708				\$223,889	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129886				\$57,622	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129897				\$80,489	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130181				\$544,759	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130331				\$500,279	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130566			\$189,392	\$556,849	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130854				\$342,328	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130884				\$380,134	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131338				\$159,606	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131455				\$536,991	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131586	University of Pittsburgh	DK131586		\$49,341	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131685				\$701,296	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131708	Maggie's Pearl, LLC.	DK131708		\$59,712	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131946				\$185,270	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132001	University of North Carolina at Chapel Hill	DK132001		\$20,790	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132046	University of Minnesota	DK132046		\$14,394	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132121				\$10,430	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132651				\$399,371	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132709	Indiana University	DK132709		\$15,525	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132718				\$277,556	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132733	Massachusetts General Hospital	DK132733		\$27,683	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132781	University of Minnesota	DK132781		\$20,442	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133171				\$593,439	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133194			\$30,470	\$931,872	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133401				\$549,823	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133643				\$193,479	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133897				\$99,643	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133947	University of Chicago	DK133947		\$597,712	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134321	Northwestern University	DK134321		\$58,223	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134366				\$342,105	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134448				\$340,652	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134482	Hennepin Healthcare Research Institute	DK134482		\$229,882	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134661			\$275,136	\$602,699	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134759				\$209,110	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134765				\$137,588	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134767				\$289,298	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134815	University Texas Medical Branch	DK134815		\$348	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135097				\$410,505	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135200				\$47,629	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135407				\$828,796	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135440				\$496,649	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135573	University of Arizona	DK135573		\$6,867	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136007	University of Wisconsin-Madison	DK136007		\$17,440	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136208				\$318,884	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136511				\$251,565	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136731				\$340,608	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136906			\$89,525	\$424,421	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137231				\$166,857	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137520	Seattle Children's Hospital	DK137520		\$15,751	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137778				\$98,720	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137800				\$22,895	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137827				\$30,014	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137868				\$25,285	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138619	Phenomix Sciences	DK138619		\$41,226	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138638				\$16,214	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138818				\$658,666	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138998				\$167,525	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139028				\$122,567	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139207				\$349,412	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139604				\$232,363	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139607				\$202,876	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK140206				\$36,621	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK140921				\$56,643	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141297	HydroGene Therapeutics	DK141297		\$10,870	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK40484				\$665,803	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44650				\$285,076	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK45343				\$322,942	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK52766			\$54,467	\$498,631	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57061				\$503,985	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57993				\$556,479	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58816				\$784,987	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59597				\$505,132	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59615				\$281,351	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK73983				\$300,329	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK74008	Johns Hopkins University	DK74008		\$298,617	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78646			\$8,950	\$217,096	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78924				\$348,703	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK83912	University of Michigan	DK83912		\$50,970	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567	Case Western Reserve University	DK84567		\$63,300	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567				\$1,348,626	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90358			\$31,726	\$687,627	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92255				\$75,279	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92460				\$494,389	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK94157	Case Western Reserve University	DK94157		\$34,075	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98468			\$35,913	\$532,476	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99160				\$303,823	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	W81XWH-21-1-0665	University of Alabama at Birmingham	W81XWH-21-1-0665		\$336,750	\$43,929,342	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS085070				\$909,526	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS092882				\$493,505	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100620				\$2,517,021	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100699	University of Cincinnati	NS100699		\$843	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS101721				\$29,372	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102360				\$31,364	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103212				\$346,521	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103870			\$431,496	\$1,170,263	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105853				\$24,525	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107624	Yale University	NS107624		\$3,774	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109491				\$21,610	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110085				\$313,599	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110435			\$1,365,848	\$2,671,998	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110772	University of Cincinnati	NS110772		\$28,914	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110825	University of Maryland-Baltimore	NS110825		\$1,875	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110930				\$121,942	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110949				\$422,652	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111039	Duke University	NS111039		\$14,250	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111981	Cleveland Clinic Foundation	NS111981		\$24,957	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144			\$5,122	\$248,643	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112153				\$316,424	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112176				\$62,357	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112339				\$138,300	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112497			\$179,932	\$353,760	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112826	Yale School of Medicine	NS112826		\$258,793	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113315				\$29	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113637	University California San Francisco	NS113637		\$155,670	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113724	Evogen, Inc.	NS113724		\$9,795	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113760				\$316,989	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113803				\$658,863	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113828				\$390,957	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114147			\$136,051	\$169,758	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114552	University of Chicago	NS114552		\$18,392	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115126				\$700,892	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198	Icahn School of Medicine	NS115198		\$13,390	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198	Mount Sinai School of Medicine	NS115198		\$29,639	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198			\$426,837	\$502,617	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115388	Massachusetts General Hospital	NS115388		\$3,620,225	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115877			\$15,516	\$724,625	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117432			\$130,286	\$334,229	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117450	University of Cincinnati	NS117450		\$11,204	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117461				\$226,507	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117844	Ohio State University	NS117844		\$127,418	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117944			\$42,000	\$279,305	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118513			\$173,676	\$489,315	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118669	Banner Sun Health Research Institute	NS118669		\$143,009	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118790				\$1,542	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119169			\$532,083	\$893,636	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119714	Scripps Research	NS119714		-\$4,037	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119714	University of Florida	NS119714		\$220,964	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120331	St. Joseph's Hospital and Medical Center	NS120331		\$41,796	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120496	University of California San Diego	NS120496		\$84,100	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120496	University of TX SW Medical Center	NS120496		-\$23,002	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120557	Johns Hopkins University	NS120557		\$394	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120877				\$400,837	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120901	Massachusetts General Hospital	NS120901		\$3,498	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120901	University of Utah	NS120901		\$111,871	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120992			\$26,529	\$847,596	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121125				\$525,707	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121720	Stanford University	NS121720		\$2,180	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121928	University of Miami	NS121928		\$3,961	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122096				\$573,618	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122174				\$553,156	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122226	Binghamton University	NS122226		\$16,951	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122419	New York University	NS122419		\$175,610	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122602	Piraeus Medical, Inc.	NS122602		\$150,518	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122764	Johns Hopkins University	NS122764		\$81,108	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123052				\$802,711	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123066				\$626,218	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123743	Stanford University	NS123743		\$758,878	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123958	University of New Mexico	NS123958		\$9,752	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124065	University of Minnesota	NS124065		\$49,958	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124613	University of Florida	NS124613		\$53,495	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124650			\$69,786	\$212,321	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124688				\$172,560	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124911				\$54,759	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125023	University of Cincinnati	NS125023		\$13,330	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125417			\$243,072	\$981,647	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125437	University of Minnesota	NS125437		\$92,805	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125597	University of Wisconsin-Eau Claire	NS125597		\$14,984	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125895	NaviNetics, Inc.	NS125895		\$34,717	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125895	Wincs International, LLC.	NS125895		-\$311	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126227				\$302,639	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126406	University of California Los Angeles	NS126406		\$140,261	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126417				\$59,561	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126609	University of Minnesota	NS126609		\$1,057	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127331				\$179,673	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127849	Carnegie Mellon University	NS127849		\$130,569	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127922				\$95,032	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128071			\$55,552	\$328,859	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128199	Medical College of Wisconsin	NS128199		\$87,378	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128212				\$45,635	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128228	Duquesne University of the Holy Spirit	NS128228		\$10,359	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128612			\$235,520	\$1,090,002	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128964	University of California Los Angeles	NS128964		\$110,557	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129032	Massachusetts Institute of Technology	NS129032		\$4,614	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129252				\$29,362	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129448	Piraeus Medical, Inc.	NS129448		\$161,940	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129549			\$51,030	\$796,890	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129622				\$226,801	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129671				\$600,851	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS130297				\$249,196	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132128			\$80,460	\$371,478	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132146	Leland Stanford Junior University	NS132146		\$85,830	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132326	University of Texas Health at Houston	NS132326		\$90,330	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132326				\$206,903	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132330			\$319,376	\$1,063,576	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132415	Harvard Medical School	NS132415		\$11,674	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS133986	Massachusetts General Hospital	NS133986		\$8,528	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS133986				\$447,829	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135130				\$57,068	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135749	Conway Medical, LLC	NS135749		\$39,872	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135898				\$1,177	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136020	Massachusetts General Hospital	NS136020		\$2,039	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136021	Massachusetts General Hospital	NS136021		\$26,080	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136022				\$207,678	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136683	Shirley Ryan AbilityLab	NS136683		\$109,525	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS137447				\$10,727	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS137907				\$72,963	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS138490				\$48,949	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS31744			\$125,982	\$492,211	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS65705	University California San Francisco	NS65705		\$6,428	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS76491			\$231,312	\$515,341	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168			\$2,422,016	\$3,796,639	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84974			\$2,423,988	\$3,427,769	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88627				\$110,322	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89757				\$884,833	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92091	University of Miami	NS92091		\$100,834	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92625				\$779,165	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS93334	Boston University	NS93334		\$43,192	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95495				\$191,411	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95869	University of Cincinnati	NS95869		\$10,617	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS96761	Carnegie Mellon University	NS96761		\$161,675	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97273				\$1,287,459	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97719	Cleveland Clinic Foundation	NS97719		\$300	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97876	Columbia University	NS97876		\$196,913	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043	University of Cincinnati	NS99043		\$16,459	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043	University of Michigan	NS99043		\$1,161	\$47,525,635	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	75N93021C00018	Children's Hospital of Boston	75N93021C00018		\$174	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1104681	Duke University	A1104681		\$447,699	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1108682				\$830,648	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1108891				\$199,637	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108906	Benaroya Research Institute at Virginia Mason	AI109565		\$325,184	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565				\$242,566	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI110173	Emory University	AI110483		\$664,105	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI110483				\$6,419	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI112844	University of Virginia School of Medicine	AI112844		\$13,006	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116501	Washington University in St. Louis	AI116501		\$12,895	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	Cincinnati Children's Hospital Medical Center	AI117804		\$29,721	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120698				\$1,124	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI121054				\$1,110	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127365				\$71,467	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI128729			\$145,581	\$597,240	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI129191				\$156,033	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132165				\$162,171	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132348				\$652,666	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132402	University of Iowa	AI132402		\$29,531	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134770	University of Massachusetts	AI134770		\$53,173	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134937			\$60,199	\$553,542	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138965				\$743,631	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138993	Arizona State University	AI138993		\$237,420	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141591	University of Michigan	AI141591		\$139,883	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141765				\$93,848	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143791			\$117,545	\$541,033	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143882				\$160,744	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145108	University of Maryland-Baltimore	AI145108		\$123,189	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147652				\$535,913	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148963	Columbia University	AI148963		\$9,642	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148963	Icahn School of Medicine	AI148963		\$2,791	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150100				\$328,872	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150649				\$22,582	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151208				\$15,718	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151923				\$23,204	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154470	Children's Hospital of Philadelphia	AI154470		\$1,565	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154598	University of Virginia School of Medicine	AI154598		\$11,800	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154659	Vanderbilt University Medical Center	AI154659		\$37,839	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155378				\$187,290	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155826				\$865	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI156137				\$2	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI158813				\$147,547	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159230				\$44,804	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI161367			\$139,110	\$365,405	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI162678			\$7,841	\$466,582	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI162699	University of Minnesota	AI162699		\$46,287	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI163081	Northwestern University	AI163081		\$3,335	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI163302	University of Florida	AI163302		\$5,720	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI164562	Emory University	AI164562		\$48,442	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165061	Stinglenn, LLC	AI165061		\$6,863	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI169530			\$404,788	\$776,361	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170424	Cedars Sinai Medical Center	AI170424		\$61,412	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170478				\$307,600	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170535				\$515,796	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170571				\$69,541	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170649				\$520,319	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171008	University of Michigan	AI171008		\$314,210	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171306				\$60,874	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
			Hennepin Healthcare						
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171826	Research Institute	AI171826		\$25,820	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI172838			\$24,249	\$172,730	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175039				\$176,637	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175813				\$398,082	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI177472				\$136,447	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI178147				\$168,012	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI178943				\$189,469	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179609				\$298,719	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179709				\$39,506	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179974				\$152,752	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI181542				\$290,396	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI181754				\$205,368	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI182489				\$73,813	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI182888			\$26,646	\$80,970	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI183801				\$71,383	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI184121				\$154,867	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI184360				\$144,478	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI21747	University of Connecticut	AI21747		\$71,528	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI33144				\$209,098	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI57266	Emory University	AI57266		\$77,942	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of California Los Angeles						
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI68636		AI68636		\$37,272	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI71106			\$50,026	\$517,288	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI89714				\$291,661	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI91594			\$84,488	\$393,098	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI176254				\$319,502	\$16,725,878	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063904			\$205,729	\$221,079	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM08685				\$491,535	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130556			\$56,995	\$64,318	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132095				\$97,949	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132100				\$182,955	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM135488				\$167,485	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136262				\$363,128	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136869				\$94,182	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of Puerto Rico						
			Medical Center	GM137368		\$39,961	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM140487				\$248,452	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM141003			\$32,400	\$384,098	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM142122	Southcentral Foundation	GM142122		\$113,245	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM142710				\$147,432	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM143949				\$430,076	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144233				\$246,708	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144351			\$256,116	\$370,786	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144393			\$97,704	\$227,067	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145385	University of North Florida	GM145385		\$7,431	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145408				\$1,115,509	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM146651				\$468,665	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM147134				\$423,349	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of North Carolina at						
			Chapel Hill	GM148971		\$101,084	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM155031				\$157,648	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM55252				\$254,779	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65841				\$5,280	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM75148				\$278,599	\$6,702,800	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	AR84222				\$934,143	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100251	Sersense, Inc.	HD100251		\$168,086	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100540	Johns Hopkins University	HD100540		\$5,085	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102615	Arizona State University	HD102615		\$260,854	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102663				\$213,627	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103099	Massachusetts General Hospital	HD103099		\$66,418	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103498			\$39,073	\$59,204	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105714	University Kansas Medical Center	HD105714		\$73,400	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105892	Case Western Reserve University	HD105892		\$17,315	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD106096			\$189,437	\$471,707	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD106162			\$12,211	\$128,479	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107034			\$47,000	\$243,470	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107897	Sequitur Health Corporation	HD107897		\$111,839	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD108477	Binghamton University	HD108477		\$44,076	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD109127	Henry Ford Health System	HD109127		\$70,516	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD110981	University of Minnesota	HD110981		\$52,084	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112161				\$35,285	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112327			\$171,477	\$522,030	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112474	MaineHealth	HD112474		\$67,235	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112824	Louisiana State University Agricultural Center	HD112824		\$13,756	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD115260	Brigham & Women's Hospital	HD115260		\$27,199	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD115283			\$113,328	\$416,565	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD44763	University of Minnesota	HD44763		\$135,050	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD84423	University Texas Medical Branch	HD84423		\$180,923	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD86843	Spaulding Rehabilitation Hospital	HD86843		\$42,065	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD96993	Sersense, Inc.	HD96993		\$74,607	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD99147				\$204,220	\$4,639,238	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG03949	Albert Einstein College of Medicine	AG03949		\$164,152	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG056366			\$66,915	\$1,004,129	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG058812				\$99,610	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG061796				\$177,925	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG062110				\$63,459	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG067593				\$657,695	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG06786			\$322,641	\$1,958,791	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG078533	University of Texas at Austin	AG078533		\$49,411	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG080037				\$16,842	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG083832				\$34,735	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG11378			\$13,020	\$1,047,190	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG13925			\$40,001	\$483,620	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG23438	Washington University in St. Louis	AG23438		\$195,960	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG24904	Northern CA Institute for Research & Education	AG24904		\$920,899	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG24904	University of Southern California	AG24904		\$415,738	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG27161	University of Wisconsin-Madison	AG27161		\$123,997	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG27924				\$8,778	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG32438	Washington University in St. Louis	AG32438		\$112,092	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG37491				\$522,667	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG38791	University California San Francisco	AG38791		\$51,867	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG41851				\$35,025	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG44170	Northwestern University	AG44170		\$5,642	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG44170			\$63,482	\$292,898	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG44615				\$754,828	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG45779				\$226,048	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG46139			\$135,123	\$1,294,885	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG46205				\$296,298	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG49672				\$29,862	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG50603				\$826,241	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG52350	University of Southern California	AG52350		\$195	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG53229				\$2,112	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG53267	Washington University in St. Louis	AG53267		\$76,821	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG54029	Massachusetts General Hospital	AG54029		\$147,884	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG54029	University of Southern California	AG54029		\$54,637	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG54199			\$225,941	\$771,030	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG54454				\$78,582	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG54787	University of Mississippi Medical Center	AG54787		\$134,471	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG55529				\$157,945	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG55549			\$177,707	\$916,833	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG56130	Sanford-Burnham Medical	AG56130		\$328,116	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG56255			\$30,866	\$30,866	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG56270	Columbia University	AG56270		\$183,976	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG56366				\$10,732	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG56933	Johns Hopkins University	AG56933		\$25,166	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG57052				\$172	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG57195	Indiana University	AG57195		\$842,764	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG57437	University of Southern California	AG57437		\$1,334,693	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG57708	Barrow Neurological Institute	AG57708		\$33,122	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG58266				\$465	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG58738				\$303,501	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG58798	Washington University in St. Louis	AG59798		\$2,177	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG59798					\$195,569	\$99,611,476	RESEARCH AND DEVELOPMENT
AGING RESEARCH	93.866	AG60626	Dana-Farber Cancer Institute	AG60626		\$6,698	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG60637			\$29,901	\$29,901	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG60920				\$362,996	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG61100	Partners Health Care Research Management	AG61100		\$231,908	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG61456			\$92,470	\$316,725	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG61848	University of Southern California	AG61848		\$362,746	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62077				\$1,600,884	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62104				\$18,611	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62171	Johns Hopkins University	AG62171		\$332,509	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62348	Boston University	AG62348		\$241,873	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62413			\$681,059	\$2,098,871	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62436			\$86,016	\$461,144	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62677				\$3,601,492	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62689	University of California Berkeley	AG62689		\$2,551	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62823	Arizona State University	AG62823		\$76,524	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG62859				\$150,439	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG63689	Brigham & Women's Hospital	AG63689		\$397,887	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG63689	University of Southern California	AG63689		-\$14,129	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG63707				\$254,975	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG63780				\$390,402	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG63911			\$8,137,294	\$17,107,219	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG64029			\$2,156	\$19,564	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG64165	Brigham & Women's Hospital Seattle Institute	AG64165		\$50,031	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG64271	Biomed/Clinical Research Minnesota HealthSolutions Corp	AG64271		\$479	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG65088				\$143,599	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG65154			\$1,562,698	\$2,117,130	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG65188	Duke University	AG65188		\$314,639	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG65219				\$410,184	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG65248	University of Southern California	AG65248		\$93,886	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG65639				\$67,754	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG66134	Columbia University	AG66134		-\$15,306	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG66134	University of North Carolina at Chapel Hill	AG66134		\$50,834	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG66395				\$482,138	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG66429				\$334,425	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG66768	Beth Israel Deaconess Medical Center	AG66768		\$7,575	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG67151	Massachusetts Institute of Technology	AG67151		\$7,973	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG67418	UCB Pharma, Inc.	AG67418		\$288	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG67418	University of California Berkeley	AG67418		\$673,506	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG67593				\$263,828	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG67631	Indiana University	AG67631		\$65,645	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG67763			\$139,533	\$842,264	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68007				\$399,443	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68034	North Dakota State University	AG68034		\$216,103	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68048				\$386,012	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68054	University of Pittsburgh	AG68054		\$129,601	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68076				\$391,780	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68128	University of Florida	AG68128		\$51,755	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68141	Beth Israel Deaconess Medical Center	AG68141		\$20,020	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68182				\$433,560	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68192				\$554,156	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68206				\$1,151,138	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68368				\$146,702	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68581	St. Jude Children's Research Hospital	AG68581		\$623,066	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG68620				\$2,865	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69052			\$18,580	\$1,002,144	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69453	Banner Alzheimer's Institute	AG69453		\$256,986	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69690	Cedars Sinai Medical Center	AG69690		\$86,959	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69690	University of Texas at San Antonio	AG69690		-\$80,250	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69701			\$4,035,826	\$6,850,801	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69767			\$136,511	\$422,677	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG69822	NYU Grossman School of Medicine	AG69822		\$66,055	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG70113				\$186,024	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG70486				\$12,188	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71190				\$734,215	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71226				\$497,290	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71513				\$171,122	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71686				\$488,702	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71744	Hebrew Rehabilitation Center	AG71744		\$3,372	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71754	Washington University in St. Louis	AG71754		\$1,809,386	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
			Wake Forest University Health Science						
AGING RESEARCH	93.866	AG71807		AG71807		\$980	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG71934			\$35,503	\$47,766	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG72122	University of Washington	AG72122		\$27,401	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG72301			\$89,858	\$256,043	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG72719				\$686,516	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
			University of Texas Health at Houston						
AGING RESEARCH	93.866	AG72799		AG72799		-\$1,077	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG72799	Yale University	AG72799		\$433,786	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG72898				\$482,610	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG72980	Banner Alzheimer's Institute	AG72980		\$192,777	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73119	University of Connecticut	AG73119		\$61,888	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73267	University of Pittsburgh	AG73267		\$405,444	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73282				\$576,926	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73341	Harvard University	AG73341		\$580	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
			Georgia Institute of Technology						
AGING RESEARCH	93.866	AG73434		AG73434		\$57,960	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
			University California San Francisco						
AGING RESEARCH	93.866	AG73482		AG73482		\$34,983	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73525				\$89,411	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73726				\$45,743	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73886	Hebrew Rehabilitation Center	AG73886		\$18,790	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG73987				\$26,978	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
			Minnesota HealthSolutions Corp						
AGING RESEARCH	93.866	AG74127		AG74127		\$29,034	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG74604	University of Pennsylvania	AG74604		\$157,926	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG74867	University of Florida	AG74867		-\$9,988	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG74867			\$241,645	\$396,135	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG74879			\$2,747,665	\$5,288,864	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG74883				\$135,305	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG75227			\$214,894	\$672,374	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
			Regents of the University of California at San Francisco						
AGING RESEARCH	93.866	AG75744		AG75744		\$192,973	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG75802			\$1,659,256	\$3,444,990	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76122				\$848,018	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76163				\$316,690	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76401				\$123,732	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76469				\$288,559	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76515			\$70,690	\$393,090	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76518	Johns Hopkins University	AG76518		\$67,269	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76537			\$178,121	\$644,711	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76636				\$466,792	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG76662				\$145,263	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG77656			\$66,185	\$726,884	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG77677	University of Miami	AG77677		\$125,305	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG77706			\$300,941	\$1,218,529	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG77771			\$384,364	\$630,755	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG78179				\$287,416	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG78555			\$22,008	\$57,157	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG78615			\$334,073	\$480,515	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG79113			\$102,933	\$491,332	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG79859				\$589,419	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG80037				\$600,777	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG80469	Regents of the University of California at San Francisco	AG80469		\$1,371	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG80556				\$563,012	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG80598	Beth Israel Deaconess Medical Center	AG80598		\$27,699	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG80842	Beth Israel Deaconess Medical Center	AG80842		\$105,924	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81203			\$67,068	\$510,398	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81223				\$759,241	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81293	University of Pittsburgh	AG81293		\$20,978	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81460				\$90,940	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81582	Columbia University	AG81582		\$39,367	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81584				\$161,372	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG81955			\$23,321	\$1,164,111	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82314				\$162,272	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82350	University of Wisconsin-Madison	AG82350		\$883,688	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82578	Minnesota HealthSolutions Corp	AG82578		\$689	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82681				\$464,013	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82704			\$154,873	\$542,199	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82708				\$278,718	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG82919				\$147,651	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG83039	University of Texas Health at Houston	AG83039		\$141,273	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG83186				\$472,915	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG83464	Wake Forest University Health Science	AG83464		\$9,293	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG83832				\$411,650	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG83928	Northwestern University	AG83928		\$3,881	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG83981	North Dakota State University	AG83981		\$243,314	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG84154	University of Missouri	AG84154		\$53,082	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG84236				\$168,562	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG84733				\$83,599	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG85307	University of Colorado	AG85307		\$39,514	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG85314				\$305,972	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG85705				\$130,748	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG85900	University of Minnesota	AG85900		\$84,221	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG85984				\$45,332	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG86085			\$980	\$116,367	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG86136				\$116,487	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG87165				\$93,211	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG87361				\$105,601	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG87387				\$126,938	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG88019	University of Florida	AG88019		\$2,609	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG88076				\$88,015	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG88403				\$48,972	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG89150				\$36,024	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
AGING RESEARCH	93.866	AG89380				\$25,275	\$99,611,476	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY11751	JAEB Center for Health Research, Inc.	EY11751		\$200,849	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY14231	JAEB Center for Health Research, Inc.	EY14231		\$173,066	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY22124	Ohio State University	EY22124		\$300	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY23384	University of Minnesota	EY23384		\$131,162	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY23533	Pennsylvania State University	EY23533		\$2,036	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY30030	JAEB Center for Health Research, Inc.	EY30030		\$71,782	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY31301				\$529,266	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY31758				\$162,270	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY33293	Johns Hopkins University	EY33293		\$52,600	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY35084	University of Southern California	EY35084		\$99,654	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
VISION RESEARCH	93.867	EY35533			\$57,100	\$435,071	\$1,858,056	RESEARCH AND DEVELOPMENT	\$490,180,429
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934	University of Texas Health at Houston	LM11934		\$71,724	\$262,590	RESEARCH AND DEVELOPMENT	\$490,180,429
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934				-\$7,452	\$262,590	RESEARCH AND DEVELOPMENT	\$490,180,429
MEDICAL LIBRARY ASSISTANCE	93.879	LM13438	Arizona State University	LM13438		\$198,318	\$262,590	RESEARCH AND DEVELOPMENT	\$490,180,429
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	MDH10327	Minnesota Department of Health	MDH10327		\$419,302	\$419,302	N/A	\$0
HIV CARE FORMULA GRANTS	93.917	GRK%212096	MN Department of Human Services	GRK%212096		\$104	\$104	RESEARCH AND DEVELOPMENT	\$490,180,429
TUBERCULOSIS DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION	93.947	NU52PS910245				\$1,205,093	\$1,286,419	RESEARCH AND DEVELOPMENT	\$490,180,429
TUBERCULOSIS DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION	93.947	PS910245				\$81,326	\$1,286,419	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	140D042490004			\$294,683	\$725,505	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	20X048F	Leidos Biomedical Research	20X048F		\$262,174	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75D30119C06088				\$15,900	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75D30120C07986	HealthPartners Institute	75D30120C07986		\$9,431	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75D30122C13330	Children's Hospital of Boston	75D30122C13330		\$9,436	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75D30122C15355	University of Wisconsin-Madison	75D30122C15355		\$3,198	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2024 - 12/31/2024

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Pass-through Entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CONTRACT	93.RD	75N91019D00024	Hennepin Healthcare Research Institute	75N91019D00024		\$17,671	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75N91019D00024	Leidos Biomedical Research	75N91019D00024		\$68,906	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75N92019D00031	Boston University	75N92019D00031		\$39,192	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75N94023F00001			\$279,793	\$416,429	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	75Q80120D00005				\$1,627,624	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	80JSC022F0146	University of Colorado	80JSC022F0146		\$255,928	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	HHNS-268-2018-00010I	University of Mississippi Medical Center	HHNS-268-2018-00010I		\$53,196	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	HHS-N-261-2012-00042I				\$788	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	HHS-N-275-2018-00003I	Duke Clinical Research Institute	HHS-N-275-2018-00003I		\$22,924	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	HHS-O-100-2014-00002I	Duke University	HHS-O-100-2014-00002I		\$305,590	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	N00189-24-P-Z565				\$861	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
CONTRACT	93.RD	PC35143	University of Iowa	PC35143		\$114,919	\$3,949,672	RESEARCH AND DEVELOPMENT	\$490,180,429
MILITARY HEALTH PROFESSIONS SCHOLARSHIPS	93.U01	Office of the Surgeon General				\$172,334	\$172,334	N/A	\$0
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$53,756,700	\$451,381,240			
TOTAL EXPENDITURES OF FEDERAL AWARDS					\$55,501,945	\$511,679,426			

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.



Mayo Clinic
Schedule of Expenditures of Florida State Financial Assistance
Year Ended December 31, 2024

Sponsor/CSFA Description/Project Description	CSFA Number	Contract / Grant / Subaward Number	Expenditures	Pass-Through to Subrecipients
STATE OF FLORIDA				
Department of Elder Affairs				
Direct Awards				
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZ108	\$ (11,867)	\$ -
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZ907	54,850	-
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZH22	684,958	-
Subtotal Direct Awards and CSFA Number 65.002			<u>727,941</u>	<u>-</u>
Total Department of Elder Affairs			<u>727,941</u>	<u>-</u>
Department of Health				
Direct Awards				
James and Esther King Biomedical Research Program	64.041	22K01	371,246	-
James and Esther King Biomedical Research Program	64.041	23K09	226,605	-
James and Esther King Biomedical Research Program	64.041	24K01	63,126	-
Subtotal CSFA Number 64.041			<u>660,977</u>	<u>-</u>
Bankhead-Coley Cancer Research Program	64.078	22B08	250,644	-
Bankhead-Coley Cancer Research Program	64.078	24B01	8,036	-
Bankhead-Coley Cancer Research Program	64.078	MOG13	(4,609)	-
Bankhead-Coley Cancer Research Program	64.078	MOG18	460,890	-
Bankhead-Coley Cancer Research Program	64.078	MOG22	1,715,535	-
Subtotal CSFA Number 64.078			<u>2,430,496</u>	<u>-</u>
Florida Consortium of National Cancer Institute Centers Program	64.128	MOG22	10,189,901	-
Endowed Chair for Cancer Research	64.130	MOAAM	161,766	-
Endowed Chair for Cancer Research	64.130	MOAAV	59,007	-
Endowed Chair for Cancer Research	64.130	MOG07	1,089,317	-
Subtotal CSFA Number 64.130			<u>1,310,090</u>	<u>-</u>
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A10	(116)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A22	(1,869)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A04	13,921	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A07	51,137	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A08	26,385	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A09	106,578	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	23A03	59,762	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	23A04	179,432	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A06	30,127	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A07	42,766	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A08	20,026	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A09	151,029	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A10	53,549	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A19	39,479	-
Subtotal CSFA Number 64.135			<u>772,206</u>	<u>-</u>
Subtotal Direct Awards			<u>15,363,670</u>	<u>-</u>
Total Department of Health			<u>15,363,670</u>	<u>-</u>
Total Expenditures of State Financial Assistance			<u>\$ 16,091,611</u>	<u>\$ -</u>

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance

December 31, 2024

1. Significant Accounting Policies

The accompanying Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (the Schedules) include the federal and Florida state grant activity of Mayo Clinic (the Clinic) under programs of the federal and Florida state government for the year ended December 31, 2024. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Because the Schedules only present a selected portion of the operations of the Clinic, they are not intended to, and do not, present the consolidated financial position, results of operations, or cash flows of the Clinic.

Expenditures reported in the Schedules are reported on the cash basis of accounting, except for the Student Financial Assistance Cluster, which are reported on the accrual basis of accounting. Under the cash basis, expenditures are recognized when paid rather than when the obligation is incurred. Such expenditures are reported following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts reported on the Schedules represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

2. 10% De Minimis Cost Rate

Indirect cost rates for Mayo are based on applicable U.S. Department of Health and Human Services negotiated rates, the 10% de minimis indirect cost rate allowed by the Uniform Guidance, or sponsor-specific (capped) rates.

3. Section 202 Direct Loans and Federal Direct Loans

The Supportive Housing for the Elderly, Section 202 Direct Loans program (Assistance Listing No. 14.157), is considered a federal award until the outstanding balance is paid in full. At December 31, 2024, Bloomer Lakeview, Inc.'s outstanding balance is \$87,921.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (continued)

3. Section 202 Direct Loans and Federal Direct Loans (continued)

During the year, the Clinic expended \$17,718,352 in Federal Direct Student Loans (Assistance Listing No. 84.268), which includes Direct Stafford Loans and Parent Loans for Undergraduate Students from the federal government. The federal government is responsible for billings and collections of the loans. The Clinic assists the federal government by processing the applications and applying funds to student accounts from the federal government. Since this program is administered by the federal government, new loans made in the fiscal year ended December 31, 2024, related to Federal Direct Student Loans are considered current year federal expenditures, whereas the outstanding loan balances are not.

Uniform Guidance Reports and Schedule



Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

**Shape the future
with confidence**

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Board of Trustees, Chief Executive Officer and President, and
Chief Financial Officer
Mayo Clinic

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statement of financial position as of December 31, 2024, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”), and have issued our report thereon dated March 3, 2025.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Clinic’s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Clinic’s internal control. Accordingly, we do not express an opinion on the effectiveness of the Clinic’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.



**Shape the future
with confidence**

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Clinic's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

March 3, 2025



Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

**Shape the future
with confidence**

**Report of Independent Auditors on Compliance for Each Major Federal Program
and State Financial Assistance Project and Report on Internal Control Over
Compliance Required by the Uniform Guidance and Chapter 10.650,
*Rules of the Auditor General of the State of Florida***

Board of Trustees, Chief Executive Officer and President, and
Chief Financial Officer
Mayo Clinic

**Report of Independent Auditors on Compliance for each Major Federal Program and State
Financial Assistance Project**

Qualified and Unmodified Opinions

We have audited Mayo Clinic’s (“the Clinic”) compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* and the Florida Department of Financial Services’ *State Projects Compliance Supplement* that could have a direct and material effect on the Clinic’s major federal program and state financial assistance projects for the year ended December 31, 2024. The Clinic’s major federal program and state financial assistance projects are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Qualified Opinion on the Research and Development Cluster

In our opinion, except for the noncompliance described in the Basis for Qualified and Unmodified Opinions section of our report, the Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on the Research and Development Cluster for the year ended December 31, 2024.

Unmodified Opinion on Each of the Major State Financial Assistance Projects

In our opinion, the Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major state financial assistance projects identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs for the year ended December 31, 2024.



**Shape the future
with confidence**

Basis for Qualified and Unmodified Opinions

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance); and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Our responsibilities under those standards, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Clinic and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for the major federal program and each state financial assistance project. Our audit does not provide a legal determination of the Clinic's compliance with the compliance requirements referred to above.

Matter Giving Rise to Qualified Opinion on the Research and Development Cluster

As described in the accompanying schedule of findings and questioned costs, the Clinic did not comply with requirements regarding the Research and Development Cluster as described in finding number 2024-003 for Subrecipient Monitoring.

Compliance with such requirements is necessary, in our opinion, for the Clinic to comply with the requirements applicable to that program.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Clinic's federal programs and state projects.



**Shape the future
with confidence**

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Clinic's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Clinic's compliance with the requirements of the major federal program and state financial assistance projects as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Clinic's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Clinic's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control over compliance. Accordingly, no such opinion is expressed.
- We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



**Shape the future
with confidence**

Other Matters

The results of our auditing procedures disclosed an other instance of noncompliance, which is required to be reported in accordance with Chapter 10.650, *Rules of the Auditor General of the State of Florida* and which is described in the accompanying schedule of findings and questioned costs, as follows:

Finding No.	Assistance Listing or CSFA No.	Program (or Cluster) Name	Compliance Requirement
2024-001	64.041	James and Esther King Biomedical Research Program	H. Reporting
	64.078	Bankhead-Coley Cancer Research Program	
	64.128	Florida Consortium of National Cancer Institute Centers Program	
	64.130	Endowed Chair for Cancer Research	
	64.135	Ed and Ethel Moore Alzheimer’s Disease Research Program	

Our opinion on the CSFA Nos. 64.078, 64.128, 64.130, and 64.135 state financial assistance projects is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on the Clinic’s response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic’s response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor’s Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did



**Shape the future
with confidence**

identify certain deficiencies in internal control over compliance that we consider to be material weaknesses and a significant deficiency.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program or state financial assistance project on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program or state financial assistance project will not be prevented, or detected and corrected, on a timely basis. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses as follows:

Finding No.	Assistance Listing or CSFA No.	Program (or Cluster) Name	Compliance Requirement
2024-003	Multiple	Research and Development Cluster	M. Subrecipient Monitoring
2024-004	64.128	Florida Consortium of National Cancer Institute Centers Program	A. Activities Allowed or Unallowed and B. Allowable Costs

A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program or state financial assistance project that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be significant deficiencies as follows:



**Shape the future
with confidence**

Finding No.	Assistance Listing or CSFA No.	Program (or Cluster) Name	Compliance Requirement
2024-001	64.041	James and Esther King Biomedical Research Program	H. Reporting
	64.078	Bankhead-Coley Cancer Research Program	
	64.128	Florida Consortium of National Cancer Institute Centers Program	
	64.130	Endowed Chair for Cancer Research	
	64.135	Ed and Ethel Moore Alzheimer’s Disease Research Program	
2024-002	Multiple	Research and Development Cluster	C. Cash Management

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards require the auditor to perform limited procedures on the Clinic’s response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic’s response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

July 31, 2025

Mayo Clinic

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2024

Section I – Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified

Internal control over financial reporting:

Material weakness(es) identified? **Yes** X **No**

Significant deficiency(ies) identified? **Yes** X **None Reported**

Noncompliance material to financial statements noted? **Yes** X **No**

Federal Awards

Internal control over major federal program:

Material weakness(es) identified? X **Yes** **No**

Significant deficiency(ies) identified? X **Yes** **None Reported**

Type of auditor’s report issued on compliance for major federal program:

Qualified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 X **Yes** **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor’s Results (continued)

Identification of major state projects:

State CSFA Numbers	Name of State Project
64.078	Bankhead-Coley Cancer Research Program
64.128	Florida Consortium of National Cancer Institute Centers Program
64.130	Endowed Chair for Cancer Research
64.135	Ed and Ethel Moore Alzheimer’s Disease Research Program
Dollar threshold used to distinguish between Type A and Type B programs:	<u>\$750,000</u>

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

None identified.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs

Finding 2024-001 – Preparation of the Schedule of Expenditures of Florida State Financial Assistance

Identification of the state of Florida projects:

State of Florida Agency: Department of Health

CSFA Nos.: 64.041 (James and Esther King Biomedical Research Program), 64.078 (Bankhead-Coley Cancer Research Program), 64.128 (Florida Consortium of National Cancer Institute Centers Program), 64.130 (Endowed Chair for Cancer Research), and 64.135 (Ed and Ethel Moore Alzheimer’s Disease Research Program)

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 215.97 of the Florida Single Audit Act states the following:

- (a) Promote sound financial management, including effective internal controls, with respect to state financial assistance administered by nonstate entities.
- (b) Provide for identification of state financial assistance transactions in the state accounting records and recipient organization records.

Chapter 10.650, *Rules of the Auditor General of the State of Florida*, requires that the Schedule of Expenditures of State Financial Assistance (Schedule) is prepared with the requirements of Department of Financial Services Rules, Chapter 69I-5, Florida Administrative Code, State Financial Assistance.

Section 69I-5.003 states the following:

“A nonstate entity that receives or expends state financial assistance must, for the period covered by the entity’s financial statements, prepare a Schedule of Expenditures of State Financial Assistance. If a nonstate entity also expends federal awards, the entity may, after considering federal presentation requirements, present the expenditures of state financial assistance and federal awards on combined or separate schedules. At a minimum, the Schedule of Expenditures of State Financial Assistance must:

- (1) List individual state projects by state agency, including identifying contract or grant number.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

- (2) For state financial assistance received as a subrecipient, list the name of the pass-through entity and the identifying contract or grant number assigned by the pass-through entity.
- (3) Provide the total state financial assistance expended for each individual state project and the Catalog of State Financial Assistance (CSFA) number.
- (4) Provide the total state financial assistance transferred to subrecipients for each state project.
- (5) Include as expenditures in the schedule, the value of state financial assistance expended in the form of non-cash assistance. The value of state non-cash assistance will be established in accordance with paragraph 69I-5.004(2)(c), F.A.C.
- (6) Include notes that describe the significant accounting policies used in preparing the schedule.”

Condition:

Expenditures were misclassified to the incorrect CSFA Nos. for five of six state of Florida projects reported in the Schedule.

Cause:

The Clinic’s internal controls in place over the preparation of the Schedule were not sufficient to properly accumulate and accurately report expenditures by the correct CSFA number.

Effect or potential effect:

Reporting of expenditures to the incorrect CSFA Nos. results in a misstated Schedule and can also potentially result in insufficient testing of the major state of Florida projects or improper identification of major state of Florida projects for audit purposes.

Questioned costs:

None.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Context:

The following table illustrates the impact of the misclassification of expenditures by CSFA No.:

CSFA No.	Expenditures as Originally Reported	Adjustments	Expenditures as Revised	% Change
64.041	–	\$660,977	\$660,977	100%
64.128	–	\$10,189,901	\$10,189,901	100%
64.078	\$12,935,742	(\$10,505,246)	\$2,430,496	(81%)
64.130	\$667,675	\$642,415	\$1,310,090	96%
64.135	\$1,760,253	(\$988,047)	\$772,206	(56%)
65.002	\$727,941	–	\$727,941	–
Total	\$16,091,611	–	\$16,091,611	–

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Recommendation:

Management should implement more robust internal controls to ensure all state of Florida expenditures are appropriately classified and reported in the Schedule.

Views of responsible officials:

Management agrees and will review and strengthen the controls over data capture for the creation of the Schedule.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2024-002 – Cash Management

Identification of the federal program:

Federal Agencies: U.S. Department of Health and Human Services, U.S. Department of Defense and National Science Foundation.

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RDC, 47.070, 93.350, 93.840, 93.121, 93.172, 93.173, 93.226, 93.242, 93.273, 93.279, 93.286, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, and 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the recipient or subrecipient is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should align with the guidance in “Standards for Internal Control in the Federal Government,” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

The Clinic did not perform its monthly review control timely related to payments made to subrecipients.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Cause:

The development of new internal reports related to subrecipient payments caused a delay in the performance of the internal control during the fiscal year.

Effect or potential effect:

Untimely review of subrecipient payments may not timely detect payments to subrecipients that may not be made in accordance with the subaward agreement and not timely identify any cash management violations by the subrecipients such as not minimizing the time elapsing between the transfer of funds from the Federal agency or the pass-through entity and the disbursement of such funds by the subrecipients.

Questioned costs:

None.

Context:

During fiscal year 2024, the timing of the monthly review control performed was as follows:

- Payments made during the months of January–May 2024 were reviewed in July 2024.
- Payments made in June 2024 were reviewed in November 2024.
- Payments made during the months of July–November 2024 were reviewed in January 2025.
- December 2024 payments were reviewed in March 2025.

Subrecipient expenditures are \$55,501,945, representing 11.3% of total Federal expenditures for the R&D Cluster of \$490,180,429 for the year ended December 31, 2024.

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Recommendation:

Management should ensure timely review of subrecipient payments based on the established internal controls and policies.

Views of responsible officials:

Reviews were delayed due to the necessary rebuilding of reports to fully support the monthly monitoring process. All reviews are now current, and monitoring is in place to ensure it remains sustainable and compliant.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2024-003 – Subrecipient Monitoring

Identification of the federal program:

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12,420, 93.279, 93.286, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the recipient or subrecipient is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should align with the guidance in “Standards for Internal Control in the Federal Government,” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Section 200.332(c) of the Uniform Guidance states:

“Evaluate each subrecipient’s fraud risk and risk of noncompliance with a subaward to determine the appropriate subrecipient monitoring described in paragraph (f) of this section. When evaluating a subrecipient’s risk, a pass-through entity should consider the following:

- (1) The subrecipient’s prior experience with the same or similar subawards;

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

- (2) The results of previous audits. This includes considering whether or not the subrecipient receives a Single Audit in accordance with subpart F and the extent to which the same or similar subawards have been audited as a major program;
- (3) Whether the subrecipient has new personnel or new or substantially changed systems; and
- (4) The extent and results of any Federal agency monitoring (for example, if the subrecipient also receives Federal awards directly from the Federal agency).”

Section 200.332(e) of the Uniform Guidance states:

“Monitor the activities of a subrecipient as necessary to ensure that the subrecipient complies with Federal statutes, regulations, and the terms and conditions of the subaward. The pass-through entity is responsible for monitoring the overall performance of a subrecipient to ensure that the goals and objectives of the subaward are achieved. In monitoring a subrecipient, a pass-through entity must:

- (1) Review financial and performance reports.”

Furthermore, it is the Clinic’s policy for principal investigators to complete a subaward monitoring checklist as part of the monthly/quarterly reviews of subrecipient performance.

Condition:

Required subrecipient monitoring activities were not consistently performed related to annual subrecipient risk assessments. In addition, subaward monitoring checklists were not consistently completed or retained to evidence the results of the monitoring performed over subrecipients by principal investigators during the fiscal year.

Cause:

Established internal controls over the completion of annual risk assessments and completion of the subaward monitoring checklist as part of the monthly/quarterly subrecipient financial reviews were not followed during the fiscal year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Effect or potential effect:

Subrecipients may not be monitored timely. A subaward may not be used for authorized purposes, or performance goals may not be achieved by the subrecipient.

Questioned costs:

None.

Context:

We sampled 35 subrecipients (totaling \$18,118,028 in federal expenditures) and noted that for 23 subrecipients (totaling \$14,057,672 in federal expenditures), the Clinic did not complete its annual risk assessment and review of subrecipient audit monitoring activities during fiscal year 2024, as required.

We sampled 40 subaward monitoring checklists required to be completed during fiscal year 2024 by various principal investigators and noted in two instances (5%) the subaward monitoring checklist was not completed.

Subrecipient expenditures are \$55,501,945, representing 11.3% of total Federal expenditures for the R&D Cluster of \$490,180,429 for the year ended December 31, 2024.

Identification as a repeat finding, if applicable:

This finding is a partial repeat of Finding 2023-003 from the prior year.

Recommendation:

The Clinic should ensure that the annual subrecipient risk assessments and subrecipient monitoring checklists are completed timely and documentation is retained to support the operating effectiveness of established internal controls.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Views of responsible officials:

As described in Finding 2024-002, the report used for subrecipient risk assessments were delayed due to the necessary rebuilding of report. All risk assessments are now current and monitoring is in place to ensure it remains sustainable and compliant. Further, control processes for subrecipients monitoring checklists have been modified to ensure complete and timely documentation is retained.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Finding 2024-004 – Activities Allowed or Unallowed and Allowable Costs

Identification of the state of Florida project:

State of Florida Agency: Department of Health

CSFA No.: 64.128

Award Number: MOG22

Award Period: 07/01/2023–06/30/2025

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 215.97 of the Florida Single Audit Act states the following:

- (b) Promote sound financial management, including effective internal controls, with respect to state financial assistance administered by nonstate entities.

Condition:

Documentation of review and approval of allowability of internal service charges by the Principal Investigator (PI) or appropriate individual with knowledge of the grant was not consistently maintained at a transactional level during the fiscal year.

Cause:

The Clinic's established internal controls related to internal service charges that require (1) the PI, or authorized lab personnel, to initiate new requests for service; (2) the intake process to capture the requestor and project to be charged; and (3) confirmation to be received before work begins were not operating effectively during the fiscal year for the research activities.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award and State Project Findings and Questioned Costs (continued)

Effect or potential effect:

Internal service costs could have been charged that are not allowable.

Questioned costs:

None.

Context:

We sampled 40 internal services transactions (totaling \$374,944) and identified four instances (totaling \$131,738) related to CSFA 64.128 where the review and approval of the internal services charges were not sufficiently documented.

Internal services expenditures for CSFA 64.128 are \$1,207,336, representing 11.85% of total state expenditures of \$10,189,901 for the year ended December 31, 2024.

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Recommendation:

The Clinic should ensure that internal service transaction requests are reviewed timely, and documentation is retained to support the operating effectiveness of established internal controls.

Views of responsible officials:

Management implemented revisions to the control processes to provide evidence of review and conclusions reached over the allowability of internal service charges on State of Florida awards. Communication has occurred to ensure awareness and understanding of control process documentation.

EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2025 Ernst & Young LLP.

All Rights Reserved.

ey.com

Summary Schedule of Prior Audit Findings – For the Years Ended December 31, 2023 and 2022**Finding 2023-001 – N2 Disbursements to or on Behalf of Students***Identification of the federal program:*

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Assistance Listing No.: 84.268, Federal Direct Student Loans (Direct Loans)

Award Periods: July 1, 2022 through June 30, 2023; July 1, 2023 through June 30, 2024

Summary of Prior Audit Finding*Condition:*

When Direct Loans are being credited to a student’s account, an institution must notify the student, or parent, in writing of (1) the date and amount of the disbursement; (2) the student’s right, or parent’s right, to cancel all or a portion of that loan or loan disbursement and have the loan proceeds returned to the holder of that loan; and (3) the procedure and time by which the student or parent must notify the institution that he or she wishes to cancel the loan. In order to identify these students, Mayo Clinic (“the Clinic”) utilizes a disbursement report that is run from a script housed in SAP Business Objects. Information technology general controls (ITGCs) over the SAP Business Objects disbursement report was not tested by the Clinic during 2023 to ensure the accuracy and completeness of the disbursement report.

Recommendation:

The Clinic should implement internal controls to ensure SAP Business Objects ITGCs are tested or implement compensating controls to ensure the disbursement report is accurate and complete.

Status

Completed. Annual tests of access to Business Objects and properly authorized changes made to the logic within Business Objects specific to the disbursement report used by management will be conducted. Testing will be performed initially by Mayo Clinic’s internal audit team and in subsequent years by the Financial Aid Director and Director of Data Analytics.

Contact Person

Anne Dahlen, Director of Student Financial Aid

Aaron Pendl, Director of Data Analytics

Finding 2023-002 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles*Identification of the federal program:*

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense

Pass-Through Entities: Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, University of Chicago, University of Michigan, and Washington University

Federal Cluster: Research and Development (R&D) Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

Evidence of review of allowability of internal service charges at a transactional level by the Principal Investigator (PI) or appropriate individual with authority on the grant was not retained during the fiscal year.

Recommendation:

Beginning in fiscal year 2024, the PI monthly/quarterly review packet was redesigned to provide evidence of review and conclusions reached over internal service charges transaction detail. Management should ensure that the newly implemented control is operating as designed.

Status

Completed. Management implemented revisions to the monthly/quarterly review packet in January 2024 to ensure review of internal service charges and retention of review documentation. Management's expectations have been communicated to those responsible for the control process regarding timely reviews and retention of documentation.

Contact Person

Susan Norby, Division Chair - Financial and Accounting Services, Research Finance
Sarah Ward, Vice Chair - Financial and Accounting Services, Research Finance

Finding 2023-003 – Subrecipient Monitoring

Identification of the federal program:

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Federal Cluster: Research and Development (R&D) Assistance Listing Nos.: 12.RDC, 12.300, 93.393, 93.396, 93.847, 93.853, 93.859

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

Subaward monitoring checklists were not consistently completed or retained to evidence the results of the monitoring performed over subrecipients by principal investigators during the fiscal year.

Recommendation:

The Clinic should ensure that the subrecipient monitoring checklist is completed timely and documentation is retained to support the operating effectiveness of established internal controls.

Status

Completed. Monthly/quarterly reviews, including completion of subaward monitoring checklists, resumed in January 2024. Management's expectations have been communicated to those responsible for the control process regarding timely checklist completion and retention of documentation. Control processes for subrecipients monitoring checklists have been modified to ensure complete and timely documentation is retained effective January 1, 2025.

Contact Person

Susan Norby, Division Chair - Financial and Accounting Services, Research Finance
Sarah Ward, Vice Chair - Financial and Accounting Services, Research Finance

Finding 2023-004 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles

Identification of the federal program:

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Pass-Through Entities: Boston University, Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, Stanford University, The University of Texas, University of Buffalo, University of Chicago, and Washington University

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, and 93.866

Award Numbers: Various

Award Periods: Various

Identification of the state projects:

State Grantor: State of Florida Department of Health (DOH) Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research Award Number: MOG07 Award Period: July 1, 2014 – until expended State Grantor: State of Florida Department of Health (DOH) Catalog of State Financial Assistance (CSFA) No.: 64.135, Ed and Ethel Moore Alzheimer’s Disease Research Program Award Numbers: 20A10, 22A04, 22A05, 22A06, 22A07, 22A08, 22A09, 22K01, 23A03, 23A04, and 23K09 Award Periods: Various

Summary of Prior Audit Finding

Condition:

Internal controls over effort reporting were not operating effectively from April 1, 2023 through May 31, 2023 and, therefore, could not be relied upon.

Internal controls over salary cap were not operating effectively from April 1, 2023 through December 31, 2023 and therefore, could not be relied upon.

Recommendation:

Management should ensure effort report certifications and approvals are performed monthly. In addition, management should review the design of the payroll salary cap application to ensure it is appropriately calculating salary expenses during the effort certification process.

Status

Completed. Management has made improvements to the salary cap application to ensure salaries are being correctly charged. The salary cap application is working effectively as of January 1, 2024.

Contact Person

Susan Norby, Division Chair - Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair - Financial and Accounting Services, Research Finance

Finding 2023-005 – Procurement, Suspension and Debarment

Identification of the federal program:

Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Federal Cluster: Research and Development (R&D) Pass-Through Entity: The University of Texas Health (93.853, NS119834)

Assistance Listing Nos.: 12.420, 93.310, 93.353, 93.393, and 93.853

Award Numbers: W81XWH-15-1-0292 (12.420), OD23121 (93.310), CA246568 (93.353), CA259201 (93.393), NS119834 (93.853), NS122096 (93.853)

Award Periods: Various

Summary of Prior Audit Finding

Condition:

Internal Control

For five (56%) of nine procurement transactions tested for operating effectiveness of internal controls, the procurement justification form used by the Clinic to document the history of the procurement and compliance with Uniform Guidance CFR 200.303, was not completed until after the purchase order was created and/or invoice received from the vendor. In addition, for these same five procurement transactions, the Clinic did not timely document its suspension and debarment check at the time of procurement as required by its procurement justification form.

In addition, for four (44%) of nine procurement transactions tested for operating effectiveness of internal controls (two of which relate to the five cited above), the procurement justification form used by the Clinic to document the procurement transaction's compliance with policies, procedures and the Uniform Guidance was outdated.

Furthermore, the monthly review of completed procurement justification forms related to procurements > \$25,000 to ensure they are documented in accordance with the Clinic's procurement, suspension and debarment policies and procedures was not operating effectively.

Compliance

For one (9%) of 11 procurement transactions tested for compliance, the procurement was an add-on purchase related to a larger procurement of the same product under a prior purchase order. The prior procurement was above the simplified acquisition threshold and the Clinic's competitive bid threshold. The Clinic did not complete a procurement justification form for the add-on purchase (which was a small purchase), and the original procurement did not have adequate support to evidence that it had been competitively bid. As such, adequate documentation did not exist for the procurement in accordance with Uniform Guidance Section 230.320(a)(2)(i) and(b).

In addition, for five procurement transactions, the Clinic did not follow its suspension and debarment procedures as required by its procurement justification form.

Recommendation:

The Clinic should ensure that all R&D awards that require procurement of goods and services follow established policies, procedures, and internal controls to comply with the Uniform Guidance procurement standards and that the procurement justification form is reviewed prior to entering into the purchase transaction. The Clinic should ensure that independent checks for suspension and debarment should be timely completed at the time of procurement in accordance with the Clinic documented policies, procedures, and internal controls.

Status

Completed. Management conducted an education and training session for procurement teams in June 2024 to reinforce procurement requirements and documentation standards. Management implemented an independent sanction and debarment check for suppliers as part of existing quarterly audits over Supplier AP vendor master tables and related changes to those tables.

Contact Person

Daniel Schmitz, Division Chair - Supply Chain Management

Scott Hammer, Director - Supply Chain Management

Finding 2022-001 – Information Technology General Controls

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster/Program: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Summary of Prior Audit Finding

Condition:

Mayo Clinic (the Clinic) did not implement all Complementary User Entity Controls (CUECs) as prescribed in the Ellucian SOC 1 Report that are required to be in place to support effective information technology general controls (ITGCs) for the Banner application. The controls that were not specifically implemented relate to user access review. Additionally, user provisioning and user termination processes were not operating as designed. As a result, Banner ITGCs cannot be relied upon in the period of audit.

There is a risk the data relevant to the SFA Cluster program stored within the student financial aid system may be inappropriately created or modified. A user access review was not performed during the current period. For the remainder of the CUECs, evidence of the operation of controls identified to address this risk during the fiscal period under audit was not appropriately retained.

Recommendation:

Management should complete the implementation for all required CUECs prescribed within the Ellucian SOC 1 Report and retain documentation of the operation of controls.

Status

Completed. Mayo Clinic IT worked with the Student Financial Aid office to review the risk rating given to the Banner application. A complete user access review based on job roles was completed in 2023. The review included each employee's assigned functions within the Banner system. The user provisioning process was updated to include the functions the user is receiving.

Enhanced documentation is now retained for user terminations and other system reports required to complete testing of the Banner controls.

Contact Person

Alec Haws, ETC Education Application Analyst

Raj Sanwal, Lead IT Analyst/Programmer

Finding 2022-002 – Procurement, Suspension and Debarment

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services

Federal Cluster: Research and Development (R&D)

Pass-Through Entities: University of Iowa (93.397) and NYU Grossman School of Medicine (93.838)

Assistance Listing Nos.: 93.310, 93.394, 93.397 and 93.838

Award Numbers: OD23121, CA212162, CA97274 and HL16847

Award Periods: Various

Summary of Prior Audit Finding

Condition:

Four federal procurements conducted in fiscal year 2022 in excess of the SAT of \$250,000 were not competitively bid as required under Uniform Guidance Section 230.320(b) nor was a competitive bid exception documented to support the lack of formal proposals in accordance with Clinic procurement policies and procedures and Uniform Guidance Section 230.320(c). In addition, for one procurement, the Clinic did not timely document its independent suspension and debarment check at the time of procurement as required by its procurement justification form.

Recommendation:

The Clinic should ensure that all R&D awards that require procurement of goods and services follow established policies, procedures and internal controls in order to comply with the Uniform Guidance procurement standards. The Clinic should ensure that independent checks for suspension and debarment should be timely completed at the time of procurement in accordance with Clinic documented policies, procedures and internal controls.

Status

Completed. The procurement policies and procedures were reviewed and no changes were needed however, the appropriate education has been completed with Supply Chain Management staff to review and educate them on the federal bid requirements. A checkpoint was also added to communicate expectations on determining when a project is federally funded. In addition, the Audit, Controls, & Finance Team does a monthly review of federal purchases over \$25,000 to ensure proper documentation is retained.

Contact Person

Bruce Mairose, SCM Division Chair, Sourcing/Network Management

Finding 2022-003 (and 2021-006) – Gramm-Leach-Bliley Act – Student Information Security (GLBA)

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Summary of Prior Audit Finding

Condition:

The Clinic has a security risk program in place that follows the National Institute of Standards and Technology (NIST) framework to assess its information technology risks. The program includes: (1) employee training and management; (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

However, for the student financial aid system used by the Clinic, the 2022 NIST risk assessment did not cover (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

Recommendation:

We recommend that the Clinic include the student information systems as part of its annual enterprise-wide risk assessment.

Status

Completed. The following steps have been completed to address the gap identified:

1. Compared the scope of the Mayo Clinic Information Security annual risk assessment and the requirements of the Department of Education, under the Gramm-Leach-Bliley Act and identified any gaps.
2. Edited the existing annual risk assessment to close the gaps.
3. Completed the risk assessment.

Contact Person

Sarah Tyson, Senior Manager – Office of Information Security

Finding 2022-004 (and 2021-007) – Enrollment Reporting

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Period: July 1, 2021 through June 30, 2022

Summary of Prior Audit Finding

Condition:

As part of the review of the monthly SFRNSLC enrollment report prior to its upload to the National Student Clearinghouse (NSC)/National Student Loan Data System, the Financial Aid Director sampled 10 students from the monthly SFRNSLC enrollment report for accuracy against the student records system and sampled 10 students from the student records system for completeness against the monthly SFRNSLC enrollment report. However, evidence was not retained of the students sampled and the specific data validated as part of the review for the period January 1 – June 30, 2022. Management implemented internal controls on July 1, 2022 to include the retention of documentation over its internal controls. This control was tested for the period July 1, 2022 through December 31, 2022 and determined to be operating effectively.

Recommendation:

Management should continue to follow its internal control implemented on July 1, 2022 which documents the review process performed by the Financial Aid Director, including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and sign-off by the Financial Aid Director to evidence performance of the monthly review.

Status

Completed. Management retains evidence to support internal controls implemented as of July 1, 2022, to document the review process performed for data submitted to the National Student Loan Clearinghouse, including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and sign-off by the Financial Aid Director to evidence performance of the monthly review.

Contact Person

Anne Dahlen, Director of Student Financial Aid/Registrar

Delores Henke, Assistant Registrar

Finding 2022-005 (and 2021-008) – Activities Allowed or Unallowed and Eligibility (Cost of Attendance)

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2021 through June 30, 2022, and July 1, 2022 through June 30, 2023

Summary of Prior Audit Finding

Condition:

Annual cost of attendance (COA) budgets (by program/by enrollment status) uploaded to Mayo Clinic College of Medicine and Science's student information system by the Program Manager of Student Financial Aid were not reviewed and approved by another individual for accuracy once

the upload was complete for the period January 1 – August 31, 2022. Management implemented internal controls on September 1, 2022 to include evidence over review and approval of COA budgets and performed the control for any remaining programs for which COA budgets required upload to the student information system by December 31, 2022. This control was tested for the period September 1, 2022 through December 31, 2022 for two of four programs subject to the new control and determined to be operating effectively.

Recommendation:

Management should continue to follow its internal control implemented on September 1, 2022 which requires signoff on the annual COA budgets uploaded into the student information system by the Program Manager of Student Financial Aid by a secondary reviewer to ensure accuracy.

Status

Completed. Annual cost of attendance budgets uploaded to Mayo Clinic College of Medicine and Science’s student information system by the Program Manager of Student Financial Aid are reviewed and approved by another individual for accuracy once the upload is complete.

Contact Person

Anne Dahlen, Director of Student Financial Aid/Registrar
Maribeth Foerster, Program Manager Student Financial Aid

Finding 2022-006 – Reporting

Information of the state program:

State Grantor: State of Florida Department of Health (DOH)

Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research

Award Number: MOG07

Award Period: 07/01/2014 – 06/30/2023

Summary of Prior Audit Finding

Condition:

The annual progress report required by the State of Florida DOH was not submitted timely and no approved extension was obtained. Additionally, there was an error in the amounts reported for Endowment Expenditures and Endowment Balance for one of seven activities under Award Number MOG07.

Recommendation:

The Clinic should implement an internal control over the monitoring of due dates of all reports required to be submitted under the State of Florida DOH project to ensure they are reviewed and submitted timely. When required, formal extensions of reporting deadlines should be obtained from the State of Florida DOH. In addition, review controls should be designed with sufficient precision to ensure accuracy of amounts reported in the annual progress report.

Status

Completed. The statute requiring an annual progress report of award MOG07 has been repealed effective 7/1/23 in Chapter 2023-246 of House Bill No. 5303. Mayo Clinic Government Engagement, Research Administration and Research Finance will partner to create a control for any future reporting required to the Florida Department of Health.

Contact Person

Layne Smith, Communication-Policy and Engagement

Brian Hultgren, Research Administration
Sarah Ward, Research Finance

Finding 2022-007 (and 2021-001) – Activities Allowed or Unallowed and Allowable Costs/Cost Principles

(Internal Service Charges)

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services

Pass-Through Entities: University of Iowa (Assistance Listing No. 93.397), Massachusetts General Hospital (Assistance Listing No. 93.853), and UCB Pharma, Inc. (Assistance Listing 93.866)

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 93.350, 93.393, 93.394, 93.395, 93.397, 93.837, 93.847, 93.853, and 93.866

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

Approval of allowability of internal service charges by the Principal Investigator (PI) or appropriate individual with authority on the grant was not consistently maintained at a transactional level during the fiscal year.

Recommendation:

The Clinic should retain sufficient evidence of the monthly/quarterly review of internal service charges by PIs and the related conclusions reached over allowability.

Status

Completed. Information Technology work is complete requiring that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. In addition, Research Finance is implementing new processes to ensure the review of internal service charges are adequately documented.

Contact Person

Sean Corcoran, Section Head – Information Technology, Research Applications

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Kristine Williams, Operations Administrator – Research Administrative Services



Corrective Action Plan

Finding 2024-001 – Preparation of the Schedule of Expenditures of Florida State Financial Assistance

Corrective Action Planned

Management agrees and will review controls over data capture for the creation of the Schedule and will strengthen controls to ensure accurate preparation.

Persons Responsible for Corrective Action

Susan Norby, Division Chair - Research Finance

Target Completion Date

October 31, 2025



Corrective Action Plan

Finding 2024-002 – Cash Management

Corrective Action Planned

In 2024, management finalized revisions to the reports used to monitor subrecipient payments. Corrective actions have been implemented as of March 31, 2025 and the reports and monitoring process are functioning as intended and all reviews are current.

Persons Responsible for Corrective Action

Susan Norby, Division Chair - Research Finance

Completion Date

March 31, 2025



Corrective Action Plan

Finding 2024-003 – Subrecipient Monitoring

Corrective Action Planned

In 2024, management finalized revisions to the reports used to complete subrecipient risk assessments. Corrective actions have been implemented as of January 1, 2025 and the reports and process are functioning as intended and assessments are current.

Control processes for subrecipients monitoring checklists have been modified to ensure complete and timely documentation is retained.

Persons Responsible for Corrective Action

Susan Norby, Division Chair - Research Finance

Completion Date

January 1, 2025



Corrective Action Plan

Finding 2024-004 – Activities Allowed or Unallowed and Allowable Costs

Corrective Action Planned

Corrective actions have been implemented as of June 30, 2025 whereby management implemented revisions to the control processes retrospectively to January 1, 2025, to provide evidence of review and conclusions reached over the allowability of internal service charges on State of Florida awards. Communication has occurred to ensure awareness and understanding of control process documentation.

Persons Responsible for Corrective Action

Susan Norby, Division Chair - Research Finance

Completion Date

June 30, 2025